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PREFACE
Numerous studies have consistently demonstrated a significant reduction in the
circulating levels of the amino acid, glycine in diabetes, and prediabetic states. Even though
glycine is a chemically simple, non-essential amino acid, it plays an essential role in multiple
critical metabolic pathways such as the biosynthesis of glutathione, heme, creatine, purines,
and other metabolites. Together, these observations led us to ask the basic question underlying
this thesis: do changes in glycine metabolism play a role in the development of type 2 diabetes
and related metabolic diseases.
The numerous important metabolic roles for glycine suggest that its levels must be
maintained within a specific concentration range to ensure availability for these functions.
Glycine levels are maintained by balancing dietary intake, biosynthesis from metabolic
intermediates, and degradation. Information from naturally occurring mutations in the glycine
degradation system have demonstrated that the level of glycine in circulation is controlled
primarily by the rate of its degradation. My thesis work focuses on the rate-limiting enzyme of
this glycine cleavage system- glycine decarboxylase (GLDC). Modulating GLDC levels in
vitro and in vivo are known to alter circulating glycine levels. The general hypothesis that forms
the basis for my thesis work is that there is a functional relationship between altered GLDC
levels and the development of diabetes.
As described in this dissertation, we demonstrated that GLDC expression is upregulated
in rodent models of metabolic stress; diabetes, obesity, and fasting (described in chapter 2),
and we went on to show that GLDC expression is regulated by the metabolic hormones,
glucagon, and insulin (chapter 3).
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Finally, we addressed potential links between GLDC expression and parameters related
to metabolic health by demonstrating that changes in GLDC expression are strongly linked to
glutathione production and cellular oxidative stress levels (chapter 4). Each of these chapters,
which represent the three specific aims of my thesis project, contain their own introduction,
methods, results, and discussion sections.

These ‘results’ chapters are preceded by a

background chapter providing an overview of glycine metabolism and followed by a
conclusion chapter describing the general significance of this work and future directions.
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– BACKGROUND

The work described in this thesis is centered on issues related to the amino acid glycine,
and its metabolism. The observations that formed the impetus for this project are that glycine
levels are consistently reduced in states of metabolic stress such as diabetes and obesity. This
led to our overall hypothesis that there are unrecognized functional links between glycine
metabolism and the maintenance of metabolic homeostasis. To more fully appreciate how the
experiments described in this dissertation were designed, and the data interpreted, I am
providing this overview of glycine, its physiological functions and metabolic fates.
1.1 Glycine metabolism is altered in diabetes and related metabolic disorders
Insulin resistance, defined as a reduced sensitivity or responsiveness to insulin, is a
crucial step in the development of the metabolic syndrome (obesity, hyperglycemia,
dyslipidemia, hypertension, and cardiovascular disease) and type 2 diabetes (1, 2). The diabetic
state is accompanied by alterations in glucose, lipid, and even protein metabolic pathways. It
is now well-established that the levels of certain amino acids are consistently altered in insulin
resistance and diabetes (3-5) (Figure 1.1). Altered metabolite profiles can accompany changes
in metabolic pathways in the disease state. A consistent change in such metabolites can be
utilized, in the form of ‘biomarkers’, as predictors of a metabolic dysregulation Towards this
goal, large-scale metabolomic studies were undertaken in the last 15 years with the aim to
identify potential metabolites to predict type 2 diabetes risk.
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Figure 1.1: Amino acids and amino acid pathways associated with insulin resistance, type
2 diabetes, and obesity.
Adapted from (5)

3

Typically, a diabetes metabolomic study design consists of measurement of statistically
significant differences in metabolite concentration from a blood sample taken at a single time
point from healthy individuals and diabetic patients. But for the identification of biomarkers
for type 2 diabetes risk, cross-sectional and longitudinal study designs were utilized to
guarantee a more heterogeneous group of participants over a longer study duration. These
studies identified branched-chain amino acids (valine, leucine, and isoleucine) as effective
markers of risk of type 2 diabetes. They are positively correlated with obesity and insulin levels.
The only amino acid that was found to be negatively correlated with type 2 diabetes risk,
obesity, and insulin resistance in these studies was glycine (6-9).
A longitudinal population-based study was conducted by Wang-Sattler et al. (2012),
where the group used 4297 serum samples taken over a span of 7 years and analyzed 140
metabolites. This study identified reduced glycine levels as a candidate biomarker for impaired
glucose tolerance and type 2 diabetic state (Figure 1.2) (10). Another study by Floegel et al.
(2013) utilized targeted metabolomics on a randomly drawn sample set of 2282 controls and
800 type 2 diabetic cases from the European Prospective Investigation into Cancer and
Nutrition (EPIC)-Potsdam. This study used an average follow-up time of 7 years. Reduced
glycine levels were identified as significant predictors of type 2 diabetes development (11).
Another metabolite profiling using a longitudinal community-based Framingham Heart Study
was carried out by Cheng et al. (2012). This cohort had n=1015 type 2 diabetes and
cardiovascular disease-free individuals who had high-throughput, unbiased metabolite
profiling performed as part of the study to identify metabolic disease risk.
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Figure 1.2: Glycine levels during progression to type 2 diabetes.
The mean residues of the glycine concentration (µM) with standard errors for the normal
glucose tolerant (NGT), impaired glucose tolerant (IGT) and type 2 diabetic (dT2D) groups
Adapted from (10).
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Glycine was significantly and inversely associated with the multiple components of
metabolic disease – body mass index, waist circumference, insulin, homeostasis model
assessment of insulin resistance, systolic and diastolic blood pressure, and triglycerides (12).
A community-based multiethnic (European American, Hispanic, and African American)
cohort with an n=196 from the Insulin Resistance Atherosclerosis Study was utilized by Palmer
et al., (2015). Amongst the metabolites profiled, decreased circulating glycine was consistently
observed in individuals that converted to an insulin resistant and type 2 diabetic phenotype
(13). Non-alcoholic fatty liver disease (NAFLD) is strongly associated with metabolic
syndromes- insulin resistance, obesity, and type 2 diabetes. Hepatic steatosis is a characteristic
feature of NAFLD. In a study with n=86 individuals with varying degrees of hepatic steatosis,
fasting circulating glycine levels show a significantly negative correlation with hepatic
steatosis (13).
In summary, these findings, together with multiple studies not described here, clearly
demonstrate that circulating glycine levels are altered in type 2 diabetes and multiple metabolic
syndrome traits. One of the questions we seek to answer is whether these findings are incidental
to the development of diabetes or if they play a direct functional role in the development of the
disease state.
A potential causative role for reduced glycine levels in the development of metabolic
disease comes from studies showing that interventions that either delay or reverse the onset of
type 2 diabetes are associated with an increase in circulating glycine levels. For instance,
individuals who have undergone bariatric surgery, as a treatment option for obesity, which in
many cases can reverse the onset of type 2 diabetes, show a significant increase in plasma
glycine levels (14).
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Another example is of exercise intervention in obese individuals, which increased
circulating glycine levels as compared to the obese subjects who did not train (15). Even more
suggestive are studies showing that glycine supplementation improves insulin response and
glucose tolerance. Glycine administration has been shown to enhance glucose tolerance in
healthy subjects and reduce glycosylated hemoglobin in patients with type 2 diabetes (reviewed
in (16)). Oral glycine supplementation has been shown to increase glucagon concentration and
dramatically reduce the glucose area response (17). Glycine is one of the precursors of the
antioxidant glutathione biosynthesis (as explained in the later sections). In diabetic patients and
in aged individuals, a deficiency of the glutathione precursor, glycine, could explain the
oxidative stress and damage observed in these individuals.
Supplementing the diets of elderly individuals with glycine for 14 days restored
glutathione synthesis and pools to levels comparable to younger individuals and thereby
reducing oxidative damage (18). In another study, 12 diabetic and 12 non-diabetic subjects
were infused with [2H2]-glycine to measure glutathione synthesis, intracellular concentrations
and markers of oxidative stress. Dietary supplementation with glycine for 2 weeks enhanced
the antioxidant defenses of the cells and restored the synthesis of glutathione to a large extent
(19).
Clearly, glycine levels are a reliable indicator of metabolic health. In the next section,
we will look at some of the metabolic roles and fates of glycine.
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1.2 Physiological roles of glycine
Glycine is the simplest amino acid with hydrogen in place of a side chain common to
all other amino acids. It is considered a non-essential amino acid as it is synthesized
endogenously from various sources. But some studies show that the metabolic demand for
glycine is greater than the synthesis rate. Although mild insufficiency of glycine is not
threatening for life, a chronic shortage may result in suboptimal growth, impaired immune
responses, and other adverse effects on health and nutrient metabolism. The following is an
overview of some of the known physiological functions of glycine.
1.2.1 Glycine participates in protein biosynthesis
In growing animals, 80% of glycine is used for protein synthesis. Glycine has a unique
conformational advantage in enzymatic structure and function. Glycine residues are not
restricted in their conformational freedom as compared to other amino acids with bulky side
chains, and therefore, can provide a wide degree of flexibility for adjacent residues. This is
especially useful for active site regions within enzymes where glycine residues provide the
flexibility necessary for active site conformational changes (20). Collagen, the most abundant
protein in the human body, is composed of 35% glycine (21). Glycine plays a crucial role in
stabilizing the triple helical structure of collagen. For the formation of healthy collagen, every
third amino acid in its superhelical structure is glycine to allow close proximity of the three
chains (22).
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1.2.2 Glycine is required for the first step in heme biosynthesis
The first and rate-limiting step of heme biosynthesis takes place in the mitochondria
where glycine condenses with succinyl-coA from the Kreb’s cycle forming deltaaminolevulinic acid (23). Eight glycine molecules are needed for the synthesis of one heme
molecule. Heme is a component of various proteins in the electron transfer chain ensuring
mitochondrial protein stability and function. A decrease in mitochondrial heme content could
lead to mitochondrial dysfunction and reduced respiratory rates (24). Heme is a physiological
ligand for Rev-erbα, which regulates several genes in the circadian pathway and lipid

metabolism. Rev-erbα can sense and utilize heme to integrate circadian and metabolic
pathways (25). Reticulocytes import glycine through the glycine transporter 1 for heme
biosynthesis. An insufficiency of glycine supply to the erythroid cells causes a decline in heme
production. Disruption of the glycine transporter in mice caused a lethal phenotype by the
development of microcytic anemia (26). The fact that interruption in glycine supply to the
erythroid cells is lethal supports that glycine uptake is critical and that endogenous production
of glycine is insufficient to keep up with the metabolic demand for glycine (26).
1.2.3 Glycine is required for glutathione biosynthesis
The antioxidant glutathione is a tripeptide that consists of glutamate, cysteine, and
glycine. It is present in all mammalian tissues, but its levels are especially higher in the liver
(27). The liver plays a critical role in interorgan glutathione homeostasis (28). Glutathione
exists in either the predominant reduced (GSH) form present in millimolar quantities in the cell
or the oxidized (GSSG) form which comprises 1% of the glutathione pool (29).
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Figure 1.3: Methionine and transsulfuration pathway
Methionine is converted to cysteine and eventually into glutathione by the methioninetranssulfuration pathway. The enzyme depicted (1), methionine adenosyltransferase; (2),
transmethylation reactions; (3), S-adenosylhomocysteine hydrolase; (4), cystathione
synthase;(5), cystathionase; (6), glutamylcysteine synthetase; (7), GSH synthetase; (8),
methionine synthase; (9), betaine-homocysteine methyltransferase (30).
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Within the cell, about 85-90% of glutathione is compartmentalized in the cytosol,
around 10% is in the mitochondria (31) and a fraction is in the endoplasmic reticulum (32).
The glutathione biosynthesis pathway is depicted in Figure 1.3. Briefly, an intermediate of the
methionine cycle, homocysteine, is converted into cysteine by the transsulfuration pathway,
and eventually into glutathione by the glutathione synthetic pathway (30). Glutathione
synthetase catalyzes the last step of the addition of glycine to γ-glutamylcysteine dipeptide. We
speculate that reduced levels of glycine might have a negative impact on glutathione
production. Glutathione is required for various critical functions, some of which are: (1)
antioxidant defense and maintenance of redox balance; (2) detoxification of exogenous and
endogenous metabolites; and (3) as a source of cysteine (27, 33, 34). All aerobic organisms
generate some physiological in addition to pathological oxidative stress. The oxidative stress
intermediates that are formed- hydrogen peroxide, superoxide, toxic free radicals- are reduced
by glutathione peroxidase, in the process oxidizing GSH to GSSG. The GSSG formed is
reduced back to GSH by glutathione reductase, completing one redox cycle. This reaction
utilizes 1 molecule of NADPH (35).
1.2.4 Glycine is required for production of creatinine
The entire molecule of glycine is utilized in the production of creatine in turn
consuming around 16% of dietary glycine (36, 37). Creatine and phosphocreatine are not only
an energy buffer but also a shuttle for high-energy phosphates which are generated in the
mitochondria and shuttled to the cytosol for utilization (36, 38).
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Creatine and creatine phosphate are present in large amounts in vertebrate cells, like
skeletal muscle and cardiomyocytes, that have high and fluctuating energy demands. There is
a spontaneous loss of around 1.7% of the total body creatine pools per day which get converted
irreversibly to creatinine and excreted by the urine (36, 38). This necessitates a continuous
replacement of creatine pools either through dietary intake or de novo synthesis. De novo
synthesis accounts for around 50% of the creatine pool (39). Creatine biosynthesis is a 2-step
enzymatic process utilizing three amino acids- glycine, arginine, and methionine. The first step
is the transfer of an amidino group from arginine to the amino group of glycine by the enzyme
arginine:glycine aminotransferase generating guanidinoacetate and ornithine. The second
reaction utilizes methyl group transfer from S-adenosylmethionine to guanidinoacetate
catalyzed

by

guanidinoacetate

methyltransferase,

generating

creatine

and

S-

adenosylhomocysteine (36).
1.2.5 Glycine functions as a neurotransmitter
N-methyl-D-aspartate (NMDA) receptor is an excitatory (40) while the glycine receptor
is an inhibitory neurotransmitter (41) in the mammalian CNS. The NMDA receptor has 2
subunits- GluN1 (activated by co-agonists glycine and d-serine) and GluN2 (activated by
glutamate). GluN1 is expressed ubiquitously (42). Glycine binding to the glycine receptor
opens the channel for passive diffusion of chloride ions across the membrane [reviewed in
(41)]. The glycine transporters, main regulators of glycine in the vicinity of the NMDA
receptors, are upregulated in obesity.

12

This results in increased uptake of glycine into the cell, thereby reducing extracellular
glycine levels in the vicinity of NMDA receptors and therefore less potentiation of these
receptors (43). In contrast, a zebrafish model of severe glycine encephalopathy, gldc -/characterized by accumulation of glycine, showed NMDA and glycine receptor
overstimulation (44).
1.2.6 Glycine participates in conjugation and detoxification reactions
Conjugation is a type of biotransformation system where endogenous and xenobiotic
metabolites are converted to less toxic hydrophilic conjugates that can be excreted in the urine.
Glycine conjugation plays an important role in this detoxification process (45, 46). The enzyme
glycine N-acyltransferase catalyzes the conjugation of glycine with the xenobiotic metabolites
(e.g., benzoic acid). It plays a vital role in coenzyme A homeostasis as this reaction maintains
appropriate levels of free coenzyme A (46). Glycine also plays a role in the circulation of bile
acids from the liver to the small intestine. Bile acids facilitate the absorption of dietary lipids,
maintain cholesterol homeostasis (46), and act as signaling molecules (47). In humans, cholic
acid and chenodeoxycholic acid are the primary bile acids derived from cholesterol. Secondary
bile acids are produced during enterohepatic circulation. In humans, both primary and
secondary bile acids are conjugated with glycine or taurine (46, 48, 49). Insulin resistance and
obesity can lead to various defects in the bile acid levels or transport. Bile acid synthesis is
enhanced while transport (uptake and efflux) is impaired in these metabolic syndromes (50).
In a study by Gregus, Z., et al. (1993), hepatic glycine concentration was rapidly
increased to 2-3 fold normal levels by the usage of a potent inhibitor of the glycine cleavage
system, Cysteamine. This led to an increase in glycine-benzoic acid conjugation and
subsequent clearance from the blood by 50% and excretion of benzoyl glycine in the urine.
Glycine cleavage system maintains glycine homeostasis and its activity is a significant
determinant of glycine conjugation of xenobiotic metabolites (51).
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1.3 The potential physiological roles of glycine degradation products
1.3.1 One-carbon groups produced by glycine degradation
One-carbon metabolism incorporates cellular nutrient status as an input in the form of
carbon-units from amino acids into the folate-methionine-transsulfuration pathways and in the
process generating various outputs. These outputs include, but are not limited to, redox balance,
methyl group donors, and nucleotide biosynthesis (Figure 1.4). The amino acid inputs into onecarbon metabolism can be synthesized de novo (52).
A glycolysis pathway shunt at the 3-phosphoglycerate intermediate redirects carbon
units from glucose towards serine biosynthesis (52). In addition to de novo synthesis, amino
acid transporter, SFXN1, can also directly import serine into the mitochondria (53). Serine is
further converted into glycine by the mitochondrial enzyme, serine hydroxymethyltransferase
(SHMT2), in the process converting tetrahydrofolate (THF) to methylene THF (meTHF).
meTHF can start the folate cycle (52). Glycine can also be directly imported into the
mitochondria via the transporter, SLC25A38 (54). In some cells, glycine is cleaved into
NADH, ammonia, carbon dioxide, and meTHF by the mitochondrial tetrameric glycine
cleavage system. The carbon units of meTHF generated from glycine breakdown feed into the
folate cycle. In rodents, the enzyme threonine dehydrogenase (TDH) can catabolize threonine
to generate glycine for one-carbon metabolism and acetyl-CoA which enters the tricarboxylic
acid (TCA) cycle (55).
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Humans are deficient in this pathway as the human TDH enzyme has inactivating
mutations (56). Some other routes of glycine synthesis are via choline, dimethylglycine,
sarcosine, and betaine (52).
The biosynthetic outputs of the one-carbon metabolic pathway is synthesis of nucleic
acids, proteins, and lipids that are required to support cell growth (57). Both serine and glycine
via the folate cycle contribute one-carbon units required for nucleotide biosynthesis (58).
Methionine, which can be used for protein synthesis (59), and S-adenosylmethionine, which is
the major methyl group donor, are outputs of the methionine cycle (60). The head group of the
phospholipid, phosphatidylcholine, is synthesized from choline after three methylation
reactions involving S-adenosylmethionine as the methyl group donor (61, 62).
Many of the anabolic outputs from the one-carbon pathway require constant
regeneration of the reducing potentials to support the biosynthetic needs. This mainly occurs
through the reduction of NADPH and oxidation of NADP+ (57). One of the outputs of the
transsulfuration pathway is the antioxidant glutathione. Glutathione scavenges reactive oxygen
species (ROS) to maintain the appropriate ratio of reducing potentials for anabolic metabolism
(63). The regeneration of NADPH is required to maintain a redox balance in the intracellular
environment by keeping glutathione under the reduced state (57).
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Figure 1.4: Intersection of the one-carbon metabolic pathways to support nucleotide
biosynthesis and redox balance
Serine and glycine are the major contributors to the folate one-carbon units via the action of the
enzymes SHMT1, SHMT2 and GLDC (64).
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Another cellular requirement met from the one-carbon metabolism is the supply of
substrates for signal transduction pathways via post-translational modifications. Sadenosylmethionine donates methyl groups for histone, nucleotide and protein methylation
reactions necessary for many biological processes (65-68).
1.3.2 Glycine degradation produces energetic electrons in the form of NADH
One of the outcomes of glycine cleavage reaction is the generation of 1 molecule of
NADH. Due to the proximity of the mitochondrial glycine cleavage reaction with the electron
transport chain, the NADH generated can readily donate electrons for oxidative
phosphorylation (69, 70).
1.4 The physiology and biochemistry of the glycine cleavage system
Most of the glycine is catabolized by the glycine cleavage system which is present in
the mitochondria of some cells. This system catalyzes an oxidative cleavage reaction of glycine
to generate carbon dioxide, ammonia, NADH, and a methylene group (Figure 1.5). This is a
reversible reaction and the system then is termed as glycine synthase. Glycine cleavage
generates one-carbon groups for the folate one-carbon metabolism pathway in the form of
methylenetetrahydrofolate. Another glycine cleavage end-product is NADH which can be
directly used by the mitochondrial electron transport chain to generate energy (69).
The glycine cleavage system is a complex of three enzymes and a low molecular weight
carrier protein (71-73).
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Figure 1.5: Reaction mechanism and schematic of the glcyine cleavage complex
(A) P, T, L and H represent the protein component. Lip: lipoyl moiety, H4folate:
tetrahydrofolate, 5,10-CH2-H4folate: methylene tetrahydrofolate. (B) Schematic representation
of the glycine cleavage complex (69).
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This four-protein complex is situated closely together for the efficiency of the reactions
and attached to the mitochondrial inner membrane as is the case with respiration-linked
dehydrogenases like pyruvate dehydrogenase and alpha-ketoglutarate (70). The components of
the glycine cleavage system are introduced in the sub-sections that follow.
1.4.1 P-protein or glycine dehydrogenase (decarboxylating) (EC1.4.4.2) or GLDC:
This is a pyridoxal phosphate-containing protein that catalyzes the first partial
decarboxylation reaction of glycine along with a co-substrate, the carrier H-protein. In this
sequential random reaction, the carboxyl carbon of glycine results in generation of carbondioxide (74). The intermediate is attached to the carrier protein. GLDC can exist either as a
homodimer (e.g., in humans (75)) or as a dimer of heterodimers (reviewed in (69)).
1.4.2 T-protein or Amino methyltransferase (EC2.1.2.10) or AMT:
The second partial reaction of the decarboxylated glycine moiety which is attached to
the carrier protein is carried out by AMT. The reaction requires the presence of
tetrahydrofolate. This reaction results in the amino group of glycine to be released as ammonia.
The second product is the methylene carbon of glycine and tetrahydrofolate being converted to
5,10-methylene tetrahydrofolate (76).
1.4.3 L-protein or dihydrolipoamide dehydrogenase (EC1.8.1.4) or DLD:
The previous reaction intermediate, reduced lipoate moiety attached to the H-protein,
is re-oxidized by DLD as the last step of glycine cleavage. DLD is not a unique enzyme of the
glycine cleavage system. It is an E3-component of 2-oxoacid dehydrogenase complexes like
pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase (69).
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1.4.4 H-protein or GCSH:
This is a low molecular weight hydrogen carrier protein. The main function of the Hprotein is to shuttle the glycine cleavage reaction intermediates and reducing equivalents
between the active sites of the three enzymatic components of the system (71).
1.5 Deficiency or mutations in glycine cleavage system components cause nonketotic
hyperglycinemia and neural tube defects
Loss-of-function mutations in any genes encoding the core components (GLDC, AMT,
and GCSH) of the glycine cleavage system cause non-ketotic hyperglycinemia (NKH) or
glycine encephalopathy. This is a rare autosomal recessive disorder in which glycine levels
accumulate in body fluids (77, 78). Even though this is a rare disease, its occurrence is high
among specific geographical areas- Israel (79), Netherlands, 1/60,000 Canada, and 1/12,000
Finland (77). More than 80% of the NKH cases are due to mutations in GLDC, the rate-limiting
enzyme of the glycine cleavage system (79). Symptoms of NKH typically manifest in the first
few days of life. Neonates present with progressive loss in muscle tone, lethargy, myoclonic
jerks, respiratory issues, and coma. Almost one-third of NKH patients do not survive the first
year.
The ones that do survive either with assisted breathing or because NKH presented later in
infancy have severe neurological defects. These include seizures, hydrocephaly, and
developmental disabilities (78, 80, 81).
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GLDC has two significant functions:
(1) glycine decarboxylation and subsequent transfer of the amino-methyl moiety to
GCSH (82); and
(2) transfer of a one-carbon group, meTHF, into the folate cycle (75, 83).
Both functions are critical for normal development and brain function. In addition to the
development of NKH, a loss of glycine cleavage activity due to mutations in GLDC or AMT
can also lead to neural tube defects (84). Pai, et al., (2015) generated a gene-trap based mouse
model with decreased GLDC expression and absence of glycine cleavage activity. As expected,
glycine levels were elevated in the plasma and urine of these mutant mice. This model showed
that glycine cleavage system -activity was necessary for neural tube closure. Decreased GLDC
expression in these mice led to reduced input on one-carbon units into the folate cycle and
therefore reducing formate production required for cytoplasmic methylation cycle and
nucleotide biosynthesis (77). When pregnant dams were provided formate supplemented
drinking water from the first day of pregnancy, the folate profile of GLDC homozygous
mutants was normalized and neural tube defects were rescued. But glycine levels continued to
be elevated even after formate treatment. Mutations in GLDC can therefore result in two
distinct phenotypes- NKH and neural tube defects (77).
1.6 GLDC is overexpressed in many cancers
GLDC is aberrantly overexpressed in some types of cancers. A study conducted by Jain
et al. (2012) systematically characterized cellular metabolic activity in 60 well-established
human cancer cell lines derived from nine tumor types. Out of the 111 metabolites studied,
glycine levels were significantly correlated with transformed cell proliferation (specifically,
increased glycine uptake by the cells from the media).
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In proliferating cells, either the entire molecule of glycine can be directly incorporated
into the purine ring or glycine can be further oxidized by the glycine cleavage system to provide
one-carbon units for nucleotide biosynthesis and methylation reactions (85). One study found
high levels of GLDC in the tumor-initiating cell in non-small cell lung cancers (NSCLC). In
these cells, GLDC metabolic activity was required for maintaining the tumorigenic capacity.
Overexpressing GLDC induced significant changes in glycine metabolism and glycolysis; and
pyrimidine metabolism (86). Even in a tumor environment with poor vascularization, cancer
cells can support their survival by altering metabolism. A study conducted by Kim, D. et al.
(2015) showed glycine metabolism played a critical role in glioblastoma multiforme. GLDC
expression is increased in the pseudopalisading cells surrounding necrotic foci in the ischemic
zone of glioblastomas (87). In another study in phyllodes tumors (breast neoplasms), stromal
expression of GLDC was positively correlated with increasing tumor grade, increased Ki-67
(proliferation marker) expression, tumor recurrence, and metastasis (88). GLDC was also seen
to be highly expressed in estrogen-receptor positive breast cancer and was associated with poor
prognosis. Estrogen receptor activation by estradiol was seen to upregulate GLDC in addition
to the serine metabolic pathway (89).
The enrichment of the metabolite, sarcosine (derived from glycine), was identified in a
prostate cancer study to have a positive association with the progression of the disease from
benign to malignant and then leading to metastasis (90). In contrast to the tumorigenic potential
of GLDC as shown in prostate cancer, GLDC seems to play a tumor suppressor role in gastric
cancers.
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GLDC gene silencing shown in this study was due to promoter hypermethylation (91).
GLDC may have varied functions in different cancers and at different stages of cancer
progression. Barring this one exception, together, these findings demonstrate that glycine
metabolism and GLDC are involved in promoting a malignant phenotype.
1.7 GLDC is an evolutionarily conserved enzyme with highly flexible metabolic functions
In plants, as in all eukaryotes, glycine cleavage system is a mitochondrial complex.
Together with SHMT, it plays a critical role in the mitochondrial component of
photorespiration that converts 2-phosphoglycolate into 3-phosphoglycerate (92, 93).
Overexpression of glycine cleavage system components in Arabidopsis thaliana (a C3 plant)
increases flux through the photorespiratory pathway. This increases photosynthetic efficiency
and the production of biomass (93). In higher plants, the glycine cleavage system is
indispensable for both photorespiration and critical metabolic processes via participation in
one-carbon metabolism (92, 94, 95).
The fact that the glycine cleavage system in general and GLDC in particular plays such
fundamental and varied roles in organismal physiology; from growth regulation
(overexpression of GLDC in cancer cells) to photosynthesis in plant cells, together with its
highly evolutionary conservation from bacteria (96, 97) to humans suggests that this pathway
is deeply integrated in many basic metabolic pathways.
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1.8 The objective of the dissertation, hypothesis, and specific aims
The overall objective of my thesis work is to improve our understanding of the
regulation and physiological role of glycine decarboxylase (GLDC), the rate-limiting enzyme
in the degradation of glycine. Multiple metabolomic studies have previously shown that
circulating glycine levels are reduced in patients and animals with type 2 diabetes and related
metabolic conditions, insulin resistance, obesity, and NAFLD. Although these are purely
correlative findings, the diverse metabolic roles of glycine suggest potential functional links
between glycine metabolism and these disorders. One of these is especially interesting in the
context of diabetes; glycine is a required substrate for the biosynthesis of glutathione, which is
required for defense against cellular oxidative stress.
Increased oxidative stress is a hallmark of many metabolic disorders, including
diabetes. Together, these observations raise the possibility that changes in glycine metabolism,
mediated by altered GLDC expression, could have an impact on susceptibility or progression
of diabetes and related metabolic disorders. As a basis for my exploration of this possibility
we have formulated the following hypotheses:
(1) GLDC, the rate-limiting enzyme of the glycine cleavage system is upregulated in
metabolic disorders or metabolic stress,
(2) Regulation of GLDC expression is integrated with the hormonal signaling system
that maintains metabolic homeostasis,
(3) Alteration of GLDC expression affects cellular redox balance via changes in
glutathione production.
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The specific aims of my thesis work are:
Aim 1: Determine if GLDC gene expression is altered in a disease state or under
metabolic stress.
Aim 2: Identify the metabolic or hormonal signals that regulate gene expression and
characterize the transcriptional pathways that mediate this regulation.
Aim 3: Determine the impact of altered GLDC expression on glutathione production
and cellular redox status.
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- EXPRESSION OF GLYCINE DECARBOXYLASE (GLDC) IN RODENT
MODELS OF METABOLIC DISORDERS AND NUTRITIONAL STRESS

2.1 Introduction
The observation that glycine levels are reduced in diabetes and related metabolic
conditions forms the scientific premise of my thesis project. We hypothesized that the
relationship between metabolic status and the level of circulating glycine is dictated by changes
in the amount or activity of GLDC, the rate limiting enzyme for glycine degradation (see the
Background section for more detail). To determine if GLDC gene expression was altered by
metabolic stress we used mouse models of human metabolic diseases. We focused on hepatic
GLDC gene expression as the liver is the primary site for glycine degradation in the body and
has a major role in determining circulating glyine levels (98).
We examined hepatic GLDC gene expression in both genetic and diet-induced models
of diabetes. While the rodent models of diabetes do not perfectly mimic all aspects of the
human disease, (e.g. pancreatic islet pathology), they are excellent models for many of the
broad pathophysiological characteristics seen in the human disease (99, 100).
The db/db mouse has a genetic leptin-receptor deficiency, which results in hyperphagia,
hyperinsulinemia (by 2 weeks of age), elevated glucagon levels, obesity (by 4 weeks of age),
and hyperglycemia with beta-cell disruption (between 4 to 8 weeks) (100) (101). The ob/ob
mice have mutations in the leptin gene which also results in hyperphagia and obesity (by 4
weeks of age) along with mild hyperglycemia, compensatory hyperinsulinemia, and insulin
resistance (100). The diet-induced C57BL6/J mouse model utilizes a high-fat diet to induce
obesity and a diabetes-like state.
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Mice given 65% calories from fat diet for 15 weeks develop hyperinsulinemia, elevated
fasting blood glucose, insulin resistance, and glucose intolerance (102). In addition to these
models of metabolic stress via caloric excess, we also examined hepatic GLDC gene expression
in response to nutritional stress - fasting.
The specific goals of the experiments described in this chapter are to measure GLDC
gene expression at the RNA and protein level, under the disease models described above. If
our hypothesis is correct, we should observe an elevated level of hepatic GLDC gene
expression in the diabetes and obesity models described above. Changes in GLDC expression
in these metabolic stress models would guide us in examining the the hormonal signals that
regulate GLDC gene expression.
2.2 Materials and methods
2.2.1 Animal experiments
All the animal experiments were approved by the Wayne State University IACUC
committee and carried out under the institutional guidelines for ethical animal use.
2.2.2 A genetic model of type II diabetes
The leptin receptor-deficient db/db and control db/+ mice livers were a gift from Dr.
Jeimei Wang, Department of Pharmaceutical Sciences, Eugene Applebaum College of
Pharmacy and Health Sciences, Wayne State University, Detroit, MI. The livers were from 9week-old, male mice. These mice were not given any special diet. The control db/+ mice were
age- and gender-matched healthy litters from the same colony. The ob/ob mice data was
obtained from the NCBI Gene Expression Omnibus (GEO) public database (National Center
for Biotechnology Information, Bethesda, MD, USA; https:// www. ncbi. nlm. nih. gov/ geo/).
The raw microarray dataset (GEO profile GDS4506) was from 3-month-old, male ob/ob mice
on lab diet 5058. Their livers were harvested after an overnight fast.
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2.2.3 Diet-induced obesity mouse models
Male C57BL6/J mice were either given a low fat or a high-fat diet for 16 weeks to
induce insulin resistance and generate a diet-induced obesity mouse model. The low-fat diet
provided 10% while the high-fat diet provided 45% calories from fat. At the end of the study
duration, livers were harvested and snap-frozen for analysis by immunoblotting.
2.2.4 Fasting
Male C57BL6/J mice were either fasted for a short-term (6h), a physiologic (12h), and
extended duration (16h and 18h). All mice had unrestricted access to water. The control mice
had ab/lib access to normal chow. At the start of the fasting duration, the mice were moved to
a clean cage without food. The fast was started in such a way that all time points (controls and
fasted groups) were terminated at the same time. Livers were harvested and snap-frozen for
analysis.
2.2.5 RNA isolation and quantification
Liver tissue (50-100 mg) was lysed and homogenized in 1 ml TRIzol (Invitrogen) using
a tissue ruptor II (Qiagen) apparatus. The samples were centrifuged at 12000 X g for 5 min at
4°C to get rid of the non-homogenized tissue material and any high-fat content, if present. RNA
isolation using TRIzol was carried out based on the manufacturer’s protocol. For RNA isolation
from cultured cells, total RNA was isolated after treatment with hormones using PureLink
RNA mini kit (Invitrogen). The total RNA isolated was quantified by absorbance
spectrophotometry using a Nanodrop. Only samples with total RNA A260/230 ratio of 2.0-2.2
were used for cDNA synthesis.
2.2.6 Reverse transcription and cDNA synthesis
Total RNA was reverse transcribed to cDNA according to the reaction setup
recommendations of the manufacturer (Applied Biosystems). The random primers used in this
kit ensure that the first strand synthesis takes place efficiently with all species of RNA
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molecules present, including mRNA and rRNA. In short, the 2X RT master mix was added in
1:1 ratio to 1500 ng RNA sample per PCR tube.
The thermal cycler conditions were set as follows:
Settings

Step 1

Step 2

Step 3

Step 4

Temp.

25°C

37°C

85°C

4°C

Time

10 min

120 min

5 min

Hold

2.2.7 Quantitative real-time polymerase chain reaction
For real-time PCR analysis, reaction mixtures containing cDNA template, primers, and
SYBR Green PCR Master Mix (Thermo Scientific) were analyzed with Stratagene MX3000P
(Applied Biosystems, Carlsbad, CA). The transcript abundance of the different genes tested
was quantified after normalization to internal control PPIA. Specific oligonucleotides,
spanning an exon-exon junction, were designed using Primer-BLAST (NCBI) and
Oligoanalyzer3.1 (Integrated DNA technologies). The primers were designed such that
amplicon size would be between 70 and 200 bp. The 3’ end of the primers selected had either
a C or G residue to minimize non-specific binding to DNA and a GC content of approximately
40-60% for maximum product stability. The sequences of the real-time PCR primers used are
listed in Table 2.1
The real-time PCR program protocol included an initial activation at 95 °C for 15
minutes, followed by 40 cycles of melting with a denaturation step at 95 °C for 20 sec,
annealing at 58 °C for 25 sec and extension at 72 °C for 25 sec per cycle. The real-time PCR
was performed in duplicates and the relative fold changes were quantified using the 2-∆∆Ct
method. Results are expressed as mean + S.D.
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Table 2.1: Primers used in the RT-qPCR analysis
Primer Name

Sequence

Mouse GLDC forward

CATGATTGAGCCCACCGAGT

Mouse GLDC reverse

TGGAGACATCTTCAGGGGGT

Mouse FASN forward

GACTCGGCTACTGACACGAC

Mouse FASN reverse

CGAGTTGAGCTGGGTTAGGG

Mouse PCK1 forward

GTTTGATGCCCAAGGCAACT

Mouse PCK1 reverse

CCTTCCCAGTAAACACCCCC

Mouse PPIA forward

GCGTCTCCTTCGAGCTGTT

Mouse PPIA reverse

CTCTCCGTAGATGGACCTGC
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2.2.8 Western blot analysis using liver tissue
Samples of liver tissue (50-100 mg) were homogenized or lysed in 500 µl RIPA lysis
buffer (Thermo scientific) and freshly added protease inhibitor cocktails using a tissue
homogenizer. After complete homogenization, the tissue was centrifuged at 14000 X g for 20
min at 4 °C. The clear supernatant was carefully aspired and transferred to a new
microcentrifuge tube. For isolating protein from cells, cells were washed twice with ice-cold
PBS and then collected in PBS using a cell lifter. Cells were pelleted at 10000 rpm for 10s at
4°C. Supernatant was aspirated and 100 µl RIPA lysis buffer (Thermo scientific) along with
fresh protease inhibitor cocktails was added to the cells and vortexed for 20 sec. The lysate was
sonicated at 20% amplitude and pulse for 45 sec on-30 sec off- 45 sec on ice. Protein
concentrations were determined with a bicinchoninic (BCA) protein assay kit according to the
manufacturer’s instruction (Pierce Biotechnology) and read on a CLARIOStar plate reader at
562nm. 40 μg of protein was mixed with SDS-PAGE loading dye and the samples were heated
at 99 °C for 5 min. The samples were then loaded on a 10% SDS-PAGE gel. After separating
the proteins based on molecular weights, the proteins were then transferred onto a
nitrocellulose membrane.
The membrane was then incubated in 5% non-fat milk in PBS-T buffer at room
temperature for 2h to block non-specific binding. The blots were then probed with specific
primary antibodies at 4°C overnight. Primary antibodies used GLDC (Sigma), GAPDH (Santa
Cruz), and Actin (Sigma). Primary antibodies were diluted 1:1000 in 5% non-fat milk in PBST. Following incubation, the blots were washed 3 times for 10 min each with 1X PBST to
remove the unbound primary antibody. The blots were then incubated with HRP-conjugated
secondary antibody at room temperature for 1-2h. Following incubation, the blots were washed
3 times for 10 min each with 1X PBST to get rid of the unbound secondary antibody. The
protein bands were visualized with enhanced chemiluminescence reagents (Perkin Elmer).
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2.2.9 Statistical methods
Statistical comparisons were made with the Student’s t-test. P<0.05 was considered
significantly different. Data are presented as means + S.D. In each experiment, all treatments
were performed in triplicate. All statistical analysis was performed using GraphPad Prism
software (La Jolla, CA).
2.3 Results
2.3.1 Hepatic GLDC expression is upregulated in a mouse model of type 2 diabetes
To determine whether GLDC expression is modulated by glycemia and/or insulinemia,
we used the leptin receptor deficient db/db mouse which is routinely used as a model for type
II diabetes (99, 100). We used chow fed 9-week-old male mice. Age matched male db/+
litermates were used as controls. As shown in Figure 2.1 A, hepatic GLDC mRNA levels were
significantly elevated (2-fold, P=0.028) in the db/db mice as compared to db/+ controls. As a
positive control for diabetes-mediated changes in gene expression we also measured the
lipogenic gene fatty acid synthase (FASN), which as expected was significantly upregulated
(3.63-fold, P=0.0289) in db/db as compared to db/+ mice (Figure 2.1 B). These findings are
consistent with profiling data from ob/ob mice (extracted from GEO profiles) (Figure 2.1 C).
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Figure 2.1: Hepatic GLDC is upregulated in a mouse model of type 2 diabetes
(A) Hepatic GLDC and (B) hepatic FASN mRNA of 9-week-old db/+ (n=8) vs db/db (n=8)
male mice on no special diet. Transcript abundance was analyzed using 2∆∆Ct method and
quantitated by RT-qPCR. TBP was used as a reference gene. Error bars, mean +s.d.; *P<0.05. .
(C) The polysome-bound GLDC transcripts in the endoplasmic reticulum from livers of WT
(n=2) and ob/ob (n=2) mice. Data was extracted and plotted from GEO profiles (GEO accession
number: GSE39375 series).
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2.3.2 Hepatic GLDC is elevated in a diet-induced obesity mouse model
A high-fat diet (more than 30% of total energy from fat) for 12-16 weeks is used to
induce obesity in animal models (102). To determine if hepatic GLDC expression is elevated
in a diet-induced obesity mouse model we fed C57BL6/J mice either a low-fat control diet
(10% calories from fat) or a high-fat (45% calories from fat) diet, ad lib, for 16 weeks to induce
insulin resistance. GLDC protein levels were moderately elevated in the livers of the mice fed
a high-fat diet compared to the lean control mice (Figure 2.2 A and B). Although not
statistically significant, there was a tendency towards elevation in GLDC protein levels in the
livers of the mice on a high-fat diet. Together these results demonstrate that GLDC expression
is elevated in type II diabetes and diet-induced obesity models.
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Figure 2.2: Hepatic GLDC expression in diet-induced obesity mouse model
Western blot of GLDC expression in livers from C57BL6/J mice in (A) ‘Group 1’ lean (n=4)
and obese (n=4) mice and (B) ) ‘Group 2’ lean (n=4) and obese (n=4), fed a low fat (LF, 10%
calories from fat, n=8) and high fat (HF, 45% calories from fat, n=8) diet for 16 weeks. GAPDH
was used as a loading control.
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To further support our findings, we examined the NCBI Gene Expression Omnibus
(GEO) public database (National Center for Biotechnology Information, Bethesda, MD, USA;
https:// www. ncbi. nlm. nih. gov/ geo/) for studies on hepatic GLDC regulation. Findings from
a circadian biology study in mice (accession number: GSE52333 series) (103, 104) showed
that C57BL6/J mice fed either a normal chow or a high-fat (60% calories from fat) diet for 10
weeks displayed significantly elevated hepatic GLDC mRNA abundance at ZT=20 (Figure 2.3
A). It is noteworthy that the high-fat diet did not affect the GLDC rhythmicity. We also looked
at the effect of high fat diet on the expression of the other components of the glycine cleavage
system (AMT, DLD and GCSH). AMT also showed elevated expression in animals fed a high
fat diet (Figure 2.3 B)

36

DLD expression value

D

GCSH expression value

C

AMT expression value

B

GLDC expression value

A

Figure 2.3: Circadian rhythmicity in the transcript abundance of hepatic glycine cleavage
system components in a mouse model of diet-induced obesity
Hepatic mRNA analysis of the core components (A) GLDC, (B) AMT, (C) GCSH, and the
component shared with other pathways (D) DLD; in livers of C57BL6/J mice after 10 weeks on
a high-fat diet. Livers were harvested every 4 hrs throughout the 24 hr Zeitgeber time (ZT).
Microarray data has been extracted and plotted from GEO profile (accession number:
GSE52333 series).
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2.3.3 Hepatic GLDC is elevated during fasting
Next, we wanted to determine if the nutritional stress associated with fasting could
affect GLDC expression. We examined the effect of varying lengths of fasting duration on
hepatic GLDC expression. As shown in the figure, hepatic GLDC mRNA was significantly
stimulated with the 12h and 16h fast (Figure 2.4 A). As expected, fasting-induced
gluconeogenic gene phosphoenolpyruvate carboxykinase (PCK1) (Figure 2.4 C) but repressed
the lipogenic gene fatty acid synthase (FASN) (figure 2.4 B). Hepatic GLDC protein levels did
not increase during the short or extended fasting duration but PCK1 protein levels were
stimulated at 6h and 12h (data not shown). These results suggest that the hormonal signals or
nutritional environment associated with fasting regulate hepatic GLDC gene expression.
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Figure 2.4: Hepatic GLDC mRNA is upregulated under nutritional stress
C57BL6/J mice were either fed ad lib (0h) or fasted for 6, 12 and 16h and hepatic mRNA
abundance of (A) GLDC, (B) PCK1, and (C) FASN was quantitated by RT-qPCR. PPIB was
used as a reference gene. Error bars, mean + s.d.; * significantly different from 0h control.
**P<0.01, ***P<0.001, ****P<0.0001 Student’s t test.
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2.4 Discussion
The goal of the experiments described in this chapter was to determine whether hepatic
GLDC gene epression is altered by metabolic disease or nutrient deprivation. This is relevant
because we initially proposed that the consistent observation of reduced plasma glycine levels
in metabolic diseases was due to increased glycine degradation by GLDC. We examined
GLDC mRNA and protein levels in several standard mouse models of metabolic disease and
nutrional stress, as well as in publicly available data from GEO profiles. The results presented
here are consistent with they hypothesis that GLDC overexpression contributes to the reduction
in blood glycine levels seen in metabolic disease.
GLDC mRNA was significantly upregulated in the db/db and ob/ob mouse models,
both of which are characterized by hyperinsulinemia and/or hyperglucagonemia depending on
their age. This raises the possibility that the altered expression of GLDC in these metabolic
conditions is mediated by either one or both of these hormones. This possibility will be
explored in the next chapter.
We were intrigued by the ancillary observation that GLDC mRNA levels exhibit a
circadian pattern of expression. Through a combination of synthetic data and pathway activity
analysis of transcriptional profiling of rat liver, GLDC was identified as one of the genes in the
glycine, serine and threonine metabolic pathway to exhibit a circadian patthern of expression
(105). Many genes involved in metabolism are known to have altered rhythmicity (phase shift,
inverted, blunted) in their expression patterns on a high-fat diet (106). GLDC appears to be an
exception to this as hepatic GLDC transcripts maintained circadian rhythmicity even on highfat diet. Examination of other genes in the same GEO data set showed that another core protein
of the glycine cleavage system, AMT, had a similar pattern of expression. These observations
suggests that the rate of glycine degradation and possibly the level of glycine in circulation
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exhibit circadian fluctuations. The physiological significance of circadian fluctuations of
glycine levels is unknown.
Our initial hypothesis was based on large-scale metabolomic studies done in diabetic
and obese humans that observed a reduction in plasma glycine levels in the disease state. This
phenomenon also occurs in mice, as shown by Eckel-Mahan, et al. (2013), who showed that
high fat fed mice displayed significantly lower plasma glycine levels compared to chow fed
mice (supplementary data in (103)). Our finding, taken together with these observations from
other studies are strongly supportive of the our hypothesis that an overexpression of hepatic
GLDC contributes to the reduction in circulating glycine levels seen in type 2 diabetes and
obesity.
All these models are products of nutritional ‘excess’. We used fasting as a metabolic
paradigm for nutritional ‘stress’. Hepatic GLDC expression was elevated with 12h, 16h and
18h of fasting. An 18h fast is a standard procedure in mice (reviewed here (107)). Fasting
induces an increase in circulating glucagon, glucocorticoids, epinephrine and a decrease in
insulin concentrations (107). These findings, taken together with the observation that in the
disease models we examined exhibit hyperglucagonemia, suggest that glucagon may be a
significant hormonal regulator of GLDC. This idea is consistent with earlier studies showing
that the flux of the glycine cleavage system is stimulated by glucagon, epinephrine, vasopressin
and a high-protein meal. The next chapter explores the hormonal regulation of GLDC with
these hormones and the transcription factors mediating the effect of these metabolic hormones
on GLDC transcription.
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- HORMONAL REGULATION OF GLDC GENE EXPRESSION

3.1 Introduction
The results described in the previous chapter indicated that hepatic GLDC gene
expression in mice is altered in obesity-induced diabetes and by fasting. Obesity and type 2
diabetes are accompanied by a variety of hormonal abnormalities. Depending on the stage of
diabetes development the hormonal profile can include hyperglucagonemia and
hyperinsulinemia, both of which contribute to the hyperglycemia seen in diabetic patients by
enhancing hepatic glucose production and reducing peripheral glucose uptake (108-112).
During a fast,

glucagon and glucocorticoids are elevated and act to stimulate hepatic

gluconeogenesis (111, 113, 114). These observations, together with our findings on hepatic
GLDC expression raise the possibility that the expression of the GLDC gene is regulated by
these metabolic hormones. In this chapter, we have characterized the hormones and the
signaling pathways regulating GLDC gene transcription using primary hepatocytes and
hepatoma cell models.
Primary hepatocytes are an excellent experimental system for the study of the
mechanism of gene expression. In this cell model, hormonal conditions can be carefully
monitored and controlled to avoid the homeostatic mechanisms that are evoked by injection of
the hormone directly into a living animal. Furthermore, longer duration studies can be
performed in these cells, which are not possible with perfused livers, for example, for studying
changes in gene expression. Primary hepatocytes more closely resemble liver cells (115).
However, they do show batch to batch variability in function and viability, they do not replicate
and have a relatively short lifespan. This makes it difficult to use them as a routine
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experimental system. To overcome some of these difficulties, we also used some hepatoma cell
lines for our studies eg. Huh7 (human), H4IIe (rat), and HepG2 (human; which was used for
experiments shown in ‘chapter 4’), which retain some liver-specific expression (116-118).
3.2 Materials and methods
3.2.1 Cell culture
H4IIE (ATCC), Huh7, HEK293A (Invitrogen), and HEK293T (ATCC) cells were
maintained in Dulbecco’s modified eagle medium (DMEM) supplemented with 100 U/ml
penicillin and 100 µg/ml streptomycin (all purchased from Life Technologies) and 10% fetal
bovine serum (FBS) (Denville Scientific). Cells were incubated in a humidified atmosphere of
95% air, 5% CO2 at 37 °C.
3.2.2 Primary culture of rat hepatocytes
All procedures were performed according to the regulatory guidelines of Wayne State
University division of laboratory animal resources (DLAR), Detroit MI. Adult male Sprague
Dawley rats (180-200 gm) were housed in a DLAR facility with controlled temperature (23
°C) and humidity with a 12h light/dark cycle and ad-lib access to regular chow and distilled
water. After receiving the animals, they were acclimatized for 1 week before use.
Primary hepatocytes were isolated by Mary Gargano using a two-step collagen
perfusion method as described in detail elsewhere (Kocarek and Reddy, 1996). Immediately
after isolation, primary hepatocytes were plated onto collagen type I (Advanced BioMatrix)
coated tissue culture plates and cultured in Williams’ E medium (Gibco, A12176-01)
supplemented with 10% FBS (Denville), 100 nM Novolin (Novo Nordisk), 0.1 µM
triamcinolone acetonide (Sigma), 0.02 M glutamine, 100 IU/ml penicillin, and 100 µg/ml
streptomycin (all purchased from Life Technologies) [Plating medium]. 6h after plating, the
hepatocytes were overlaid with Matrigel (Corning) diluted 1:50 in Williams’ E [Maintenance]
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medium supplemented with 100 nM Novolin, 0.1 µM triamcinolone acetonide, 0.02 M
glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin.
The next day, hepatocytes were renewed with the addition of fresh Williams’ E
maintenance media and allowed to attach and recover from the stress of the isolation procedure.
48h after isolation, treatments were applied to the hepatocytes in Williams’ E [treatment] media
supplemented with 0.02 M glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin. The
medium containing the treatments was replenished every 24h as required.
3.2.3 Transient transfections and dual-luciferase reporter assay
Approximately 100,000 Huh7 cells/well in 0.5 ml of supplemented DMEM were plated
into 24-well plates overnight. The next day, cells were transfected with a complex containing
1.5 µl of Lipofectamine 2000, 75 ng of either GLDC 1kb firefly luciferase reporter plasmid or
245 bp FASN firefly luciferase reporter plasmid, 75 ng of pBlueScript, 50 ng EGFP-N1, 300
ng pcDNA3.1-Srebp1c expression plasmid (Addgene), and 0.5 ng pRL-CMV (Promega)
diluted in 100 µl Opti-MEM (Life Technologies) per well. 6h later, fresh media was added on
the cells. 42h after transfection, media was changed to serum-free DMEM for 6h, then cells
were lysed and collected and firefly and Renilla luciferase activities were measured using Dualluciferase reporter assay system (Promega) on a Clariostar plate reader (BMG LabTech). For
each sample, the firefly luciferase value was normalized to the corresponding Renilla luciferase
value. For transient transfection of HEK293T, 800 ng pcDNA3.1-Srebp1c, 100 ng pcDNA3.1,
and 100 ng EGFP-N1 were transfected using lipofectamine 2000. Media changes and cell
harvesting were done as explained above. Changes in GLDC mRNA were measured by realtime PCR.
3.2.4 siRNA-knockdown experiments
Primary cultures of rat hepatocytes were transiently transfected with siRNA against
GLDC, CREB1, and ATF1 (Dharmacon). Hepatocytes were plated on collagen-coated12-well
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plates (6 X 105 cells per well). Cells were transfected with Metafectene Pro (Biontex
Laboratories GmbH, Munich, Germany) according to the manufacturer’s instructions. 6h after
plating, the plating media was replaced with maintenance media containing the transfection
complexes. After overnight incubation of the complexes on the cells, the culture media was
replaced with fresh maintenance media containing Matrigel matrix (1:50 dilution), and the cells
were incubated for 24h. The next day, fresh maintenance media was replenished on the cells.
48h after transfection of the cells, dibutyryl cAMP treatment was applied via William’s E
treatment media for 12h and the cells were harvested for RNA isolation. Each treatment was
performed in triplicates and repeated at least twice using isolated hepatocytes from one rat for
each independent experiment.
3.2.5 The quantitative reverse-transcription polymerase chain reaction in primary
cultured rat hepatocytes.
Hepatocytes (1.6 million per well) were plated immediately after isolation onto
collagen-coated 6-well plates and cultured as described above. 48h after plating, hepatocytes
were treated with either dibutyryl cAMP, glucagon, and/or insulin (stocks prepared in water)
at concentrations and for time durations indicated in the individual figure legends. After
treatment durations were complete, cells were harvested and total RNA was extracted using
PureLink RNA mini kit (Invitrogen). cDNA was synthesized from total RNA using the high
capacity reverse transcription kit (Applied Biosystems) using the manufacturer’s protocol.
Gene-specific primer pairs were designed and analyzed for specificity using the NCBI
primer-BLAST tool and purchased from Integrated DNA Technologies (IDT, Coralville, IA).
The sequences of the primers used to detect the various genes are listed in Table 3.1.
PPIB was used as a reference gene. Quantitative determination of gene expression in response
to the treatments was performed by real-time PCR using Sybr green low ROX master mix
(Thermo Fisher), gene-specific primers (70 nM), and cDNA (75 ng) per reaction. Assays were
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performed in experimental duplicates on a Stratagene Mx 3000P, and the relative mRNA fold
changes were quantified using the comparative cycle threshold 2∆∆Ct method. Results were

normalized to controls and are expressed as mean + SD.

46

Table 3.1: Primers used in the RT-qPCR analysis
Primer Name

Sequence

Rat GLDC forward

GGAGGGGTCTTCTAGGGTCT

Rat GLDC reverse

CAGGTGATGGGCAGTGGAAT

Rat AMT forward

GGACTTCCCAGGAGCCAAAA

Rat AMT reverse

GGAGCCCCTTCGCATATCAA

Rat DLD forward

AGGTGAAAGCCCTGGTGTAG

Rat DLD reverse

GCCGATTGAAATGGCCTTTCTTG

Rat FASN forward

TCGACTTCAAAGGACCCAGC

Rat FASN reverse

ACTGCACAGAGGTGTTAGGC

Rat PCK1 forward

CCCAAGAGCAGAGAGACACC

Rat PCK1 reverse

CATACATGGTGCGGCCTTTC

Rat TBP forward

CCCCGGTGGAAGACAGTTTTA

Rat TBP reverse

CCAAGCCCTGAGCATAAGGT

Human PPIA forward

GTCTCCTTTGAGGTAAGGGGC

Human PPIA reverse

GCTGCACGATCAGGGGTAA

Human GLDC forward

GGCCCATCGGAGTGAAGAAA

Human GLDC reverse

TATCGCAGTTTCCGTGGCTT

Human SREBF1 forward

CTAGGAAGGGCCGTACGAGG

Human SREBF1 reverse

GCCGACTTCACCTTCGATGTC

Rat PPIB forward

TCCGTGGCCAACGATAAGAAG

Rat PPIB reverse

GCCAAATCCTTTCTCTCCTGTAGC

Rat GCSH forward

GAGTGGTAAGGAGTGTGCGG

Rat GCSH reverse

TTACGCACCGAGAGCAAAGC

Rat CREB1 isoA forward

TGAAGAACAGGGAAGCAGCAAGAG

Rat CREB1 isoA reverse

TTGGTTTTTAAGCACTGCCACTCTG

Rat CREB1 isoB forward

ACTGAGGAGCTTGTACCACCG

Rat CREB1 isoB reverse

CTGGCATGGATACCTGGGCT

Rat ATF1 forward

ATCCCAGCATTTCTGCCGTC

Rat ATF1 reverse

ATGGCAATGTACTGTCCGCTG
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3.2.6 Western blot analysis from cultured cells
Cultured cells were washed twice with ice-cold phosphate-buffered saline (PBS),
scraped off the plates, and lysed in RIPA lysis and extraction buffer (Thermo Scientific) with
protease inhibitors followed by sonication for 30 seconds. Protein concentrations were
determined with the Pierce BCA protein assay kit (Thermo Scientific). Cell lysates (40 µg)
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
and proteins were transferred onto nitrocellulose membranes (Bio-Rad). The membranes were
blocked with 5% non-fat dry milk in PBS, pH 7.4, containing 0.1% Tween-20 (PBST). The
protein bands were visualized with enhanced chemiluminescence reagents (Perkin Elmer).
Primary antibodies were used at 1:1000 dilution in 5% non-fat milk in PBST: GLDC (SigmaAldrich, HPA002318), AMT (Sigma-Aldrich), DLD (Sigma-Aldrich), GAPDH (Santa Cruz)
and Actin (Sigma-Aldrich). The primary antibodies phospho-CREB (Cell Signaling
Technology, #9191S) and total CREB (Cell Signaling Technology, #4820S) were diluted
1:1000 in 5% BSA in TBST. The signal was visualized using Azure c600 imaging system
(Azure Biosystems).
3.2.7 Statistical methods
Data were subjected to analysis of variance, and statistical comparisons were made with
the Student’s t-test. P<0.05 was considered significantly different. Data are presented as means
+ S.D. In each experiment, all treatments were performed in triplicate. All statistical analysis
was performed using GraphPad Prism software (La Jolla, CA).
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3.3 Results
3.3.1 Hormonal regulation of GLDC
As mentioned above the stimulation of the GLDC gene expression by metabolic stress
(type 2 diabetes and diet-induced obesity mouse models) and nutritional stress (fasting),
suggested that hormones known to be altered in these conditions may be direct regulators of
GLDC expression. To examine this possibility we performed an exploratory survey with the
classic metabolic hormones: 8-br cAMP (as an experimental stand-in for glucagon), insulin,
and dexamethasone (an analog for cortisol). We performed these experiments in H4IIE cells
because of their known responsiveness to metabolic stimuli at the gene expression level. The
panel is comprised of individual or combinations of hormonal treatments. As seen in Figure
3.1A, GLDC mRNA abundance was significantly upregulated with insulin and insulin +
dexamethasone. We confirmed the proper hormonal responsiveness of the cells by measuring
the mRNA abundance of PCK1 and FASN which are well characterized gluconeogenic and
lipogenic genes, respectively. As expected PCK1 mRNA was significantly suppressed by
insulin and significantly upregulated by cAMP, dexamethasone, and cAMP + dexamethasone
(Figure 3.1B). FASN mRNA was significantly upregulated with insulin, dexamethasone, and
insulin + dexamethasone (Figure 3.1C). These results demonstrate that insulin and
dexamethasone regulate GLDC gene expression in H4IIE cells.

49

A

GLDC
4

**

3

**

*

2

1

0

8-br cAMP (100 M)
Dexamethasone (500 nM)
Insulin (100 nM)

-

+
-

+
-

+

+
+

+
+

+
+
-

+
+
+

B
PCK1
mRNA relative to TBP

15

****

****
10

5

*

8-br cAMP (100 M)
Dexamethasone (500 nM)
Insulin (100 nM)

-

+
-

*

** *

0

+
-

+

+
+

+
+

+
+
-

+
+
+

mRNA relative to TBP

C

Figure 3.1: Hormonal regulation of GLDC mRNA
H4IIE cells were plated in DMEM complete media and incubated overnight. The next day the
medium was replaced with DMEM devoid of serum containing either individually or a
combination of 8-bromo cyclic AMP (100 uM), dexamethasone (500 nM) and insulin (100 nM)
or vehicle. After 6h of incubation, cells were harvested for extraction of total RNA. The
abundance of (A) GLDC mRNA, (B) PCK1 mRNA and, (C) Fasn mRNA in total RNA were
measured relative to TBP (Tata binding protein) as described under “materials and methods”.
Values for cells incubated with vehicle alone were set at 1 and the other values were adjusted
proportionately. Values are means + S.D. of three experiments. Data were analyzed used oneway ANOVA followed by Tukey’s post hoc test. Bars that share the same letter are not
significantly different.
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3.3.2 Regulation of GLDC by insulin in a rat hepatoma cell line, H4IIE.
Based on the previous hormone panel, we decided to initially focus on the response of
GLDC gene expression to insulin. When H4IIE cells were treated with either vehicle or insulin
(100 nM) for 8h, GLDC mRNA levels were strongly and significantly upregulated (9.6 fold,
P=0.0012) (Figure 3.2A). Our positive controls, FASN, and PCK1 responded to insulin as
expected. FASN was significantly upregulated with insulin treatment (2.23 fold, P=0.0223)
(Figure 3.2B). PCK1 mRNA, on the other hand, was significantly suppressed with insulin
treatment (6.66 fold, P=0.0036) (Figure 3.2C). We observed this effect of insulin on the GLDC
protein level as well (Figure 3.2D). We observed that the GLDC protein band in the rat
hepatoma cell line was migrating at a lower than expected molecular weight (between 70-100
kDa, instead of at around 110 kDa). According to NCBI, the rat GLDC protein is 98 kDa. To
confirm whether the band we are detecting is indeed GLDC protein, we used siRNA against
rat GLDC and treated the cells with either vehicle or insulin. siRNA-mediated knockdown of
rat GLDC markedly reduced basal levels, as well as the insulin, stimulated GLDC protein
levels in the serum-free DMEM media condition (Figure 3.2E). Together these results
demonstrate that GLDC expression is stimulated by insulin in hepatoma cells. During the
establishment of this experimental system, we noticed a striking effect of serum on GLDC
protein levels, which is explored in the next section (Figure 3.3)
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Figure 3.2: Regulation of GLDC by insulin in a rat hepatoma cell line, H4IIE
H4IIE cells were plated in DMEM complete media and incubated overnight. The next day the
medium was replaced with DMEM devoid of serum containing insulin (100 nM) or vehicle.
After 8h of incubation, cells were harvested for extraction of total RNA. The abundance of (A)
GLDC mRNA, (B) FASN mRNA and, (C) PCK1 mRNA in total RNA were measured as
described under “materials and methods”. Values for cells incubated with vehicle were set at 1
and the other values were adjusted proportionately. Data were analyzed using 2-∆∆Ct method and
quantitated by RT-qPCR. TBP was used as a reference gene. Error bars mean + s.d.; *P<0.05,
**P<0.01. Results were confirmed with three independent experiments. (D) Western blot of
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GLDC protein levels after insulin (100 nM) treatment for 24h in H4IIE cells. Tubulin was used
as a loading control. (E) Verification of the GLDC protein in H4IIE cells. H4IIE cells were
transfected with control siRNA or siRNA targeting GLDC as described under “materials and
methods”. After transfection, cells were incubated in either complete DMEM media or serumfree DMEM containing insulin (100 nM) or vehicle for 24h. Cells were then harvested for
preparing protein lysates and immunoblotted for the indicated proteins.
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3.3.3 Regulation of GLDC by glucose and fetal bovine serum.
We tested the effect of serum on GLDC protein levels by withdrawing serum from
H4IIE cell cultures for 3h, 6h, 12h or 24h. We observed a time-dependent decline in GLDC
protein levels after serum withdrawal with a nearly total loss of expression by 24 hours (Figure
3.3A). This suggests that one or more serum components are necessary for maintaining basal
GLDC expression. Given the stimulatory effect of insulin observed in (Figure 3.2A), one
possibility is that the crucial serum component is insulin.
In addition to hormonal abnormalities type 2 diabetes is also characterized by
hyperglycemia, raising the possibility that glucose itself could be a regulator of GLDC gene
expression. To assess the effect of glucose on GLDC expression H4IIE cells were grown in
DMEM media containing low (5.5 mM) or high (27.5 mM) glucose and treated with vehicle
or insulin for 8h. While insulin had the expected stimulatory effect on GLDC gene expression,
the concentration of glucose had no impact on either the basal or insulin-stimulated level of
GLDC expression (Figure 3.3B). As a control, we also examined the expression of the PCK1
gene, which is known to be suppressed by glucose (119, 120). As shown in (Figure 3.3C), the
responsiveness of PCK1 to insulin was enhanced by glucose. Together, these findings indicate
insulin prevents the loss of GLDC expression induced by serum starvation, and this effect is
not affected by glucose.
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Figure 3.3: Regulation of GLDC by glucose and fetal bovine serum
(A) Western blot of GLDC protein levels in H4IIE cells at indicated time points grown in
DMEM media either containing 10% fetal bovine serum or devoid of 10% fetal bovine serum.
Actin was used as a loading control. (B, C) H4IIE cells were incubated overnight in either
DMEM complete media containing 5.5 mM or 27.5 mM glucose. The next day medium was
replaced with DMEM devoid of fetal bovine serum with either 5.5 or 27.5 millimolar glucose
containing either vehicle or insulin (100 nM). After 8 hours of incubation, cells were harvested
for total RNA extraction and analysis by RT-qPCR. The abundance of (A) GLDC mRNA and
(B) PCK1 mRNA in total RNA was measured as described in “methods” section. Values for
cells incubated with vehicle were set at 1 and the other values were adjusted proportionately.
Data were analyzed using 2-∆∆Ct method and quantitated by RT-qPCR. TBP was used as a
reference gene. Error bars mean + s.d.; *P<0.05, **P<0.01, ****P<0.0001.
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3.3.4 SREBP1c regulates GLDC transcription
The strong effect of insulin on GLDC gene transcription prompted us to examine
potential transcriptional regulatory pathways that might mediate this effect.
Because many hepatic expressed genes that respond to metabolic hormones are
regulated by the FOX family of transcription factors, we sought to determine if GLDC was a
target of the FOX proteins. Systematic bioinformatics analysis of the GLDC promoter
identified two evolutionarily conserved putative binding sites for the transcription factor
FoxA2 in the proximal promoter of the human GLDC gene (Figure 3.4 A). These sites were
between - 602 and - 425 in the human GLDC promoter. To determine if these were indeed
functional FoxA2 regulatory elements, we performed luciferase reporter assays with varying
lengths of GLDC promoter (1.74 kb, 1 kb, and 600 bp) and overexpression of FoxA2. Figure
3.4 (B), is an example western blot of transient transfection of FoxA2 in either HepG2 or
HEK293A cells and measuring Foxa2 and GLDC protein levels. GLDC protein levels were
not altered with FoxA2 overexpression. We also measured GLDC promoter activity with the
other members of the FoxA family (A1, A3) and FoxO1 but did not see a change in GLDC
promoter activity or protein levels. We concluded that under all the conditions tested, GLDC
was not regulated by the FOXO family of transcription factors.
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Figure 3.4: GLDC promoter contains putative binding sites for the transcription factor
FoxA2
Schematic diagram of human GLDC promoter showing putative FoxA2 binding sites identified
using PROMO. BS- binding sites; CS - consensus sequence. (B) Fox A1 A2 and A3 plasmids
along with the control plasmid pcDNA3 were transfected in HepG2 and HEK293A cell lines
and extracts were immunoblotted for the indicated proteins. Representative data are shown
from three independent experiments.
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Another transcription factor known to mediate insulin’s effect on the transcription of a
subset of hepatic genes, including FASN, is the transcription factor SREBP1c. To begin
exploring the possibility that Srebp1c mediates the effect of insulin on GLDC transcriptional
activity, we examined SREBP1c ChIP-Seq data from ENCODE/SYDH database from insulintreated HepG2 cells (Figure 3.5 A). This global data set of functional Srebp1c binding sites
identified a Srebp1c signal in the proximal promoter of the GLDC gene. The location of this
SREBP binding signal was consistent with the location of evolutionarily conserved E-box and
SRE motifs (identified using Matinspector), which are classified as putative Srebp1c binding
sites.
To experimentally confirm that SREBP1c is a functional regulator of GLDC gene
transcription, we directly examined its effect on GLDC promoter activity in a transient
transfection reporter assay. Exogenous SREBP1c and GLDC promoter-luciferase reporter were
transfected into the human hepatoma cell line Huh7. In this system, GLDC transcriptional
activity was stimulated 4.9 fold (P=0.0019) by the introduction of exogenous SREBP1c (Figure
3.5 B). FASN, a well-characterized SREBP1c responsive gene included as a positive control,
was stimulated nearly 9 fold by SREBP1c in this system(Figure 3.5 C). Similar results were
obtained in HEK293T cells after ectopic overexpression of SREBP1c where transfection of
SREBP1c stimulated GLDC transcriptional activity by 4.32 fold (P=0.0228) (Figure 3.5 E-G).
We also examined the effect of ectopic SREBP1c on the expression of the endogenous GLDC
gene in HEK293T cells. Also, in this case, SREBP1c significantly stimulated endogenous
GLDC mRNA levels (2 fold, P=0.0024) (Figure 3.5 H). Together these data demonstrate that
SREBP1c regulates GLDC transcription and although we were not able to confirm this
experimentally (by using a dominant negative SREBP1c expression plasmid), they strongly
suggest that the observed stimulation of GLDC transcription by insulin in hepatoma cells is
mediated by an SREBP1c -dependant mechanism.
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Figure 3.5: Regulation of GLDC by the insulin-responsive transcription factor, sterol
regulatory element-binding protein 1c (SREBP1c)
(A) GLDC promoter contains putative Srebp1c binding sites. Genome-wide characterization of
Srebp1c-binding sites by ChIP-Seq in human GLDC promoter (Reed, Charos et al. 2008) in
insulin-treated HepG2 cells. The figure image was generated from ENCODE/SYDH. (B-D)
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GLDC promoter activity is regulated by SREBP1c in Huh7 cells. (B) GLDC, (C) FASN, and
(D) pGL3-control luciferase reporters co-transfected with pcDNA3.1-SREBP1c. Data are mean
+ S.D., n=3, **P<0.01, ***P<0.001, ****P<0.0001. The cells were then harvested for the
measurement of luciferase activities. Each column represents the mean ± S.D. of normalized
(Firefly/Renilla) luciferase measurements relative to vehicle control. (E-G) GLDC promoter
activity is regulated by SREBP1c in HEK293T cells. (E) GLDC, (F) FASN, and (G) pGL3control luciferase reporters co-transfected with pcDNA3.1-SREBP1c. Data are mean + S.D.,
n=3; *P<0.05, **P<0.01. The cells were then harvested for the measurement of luciferase
activities. Each column represents the mean ± S.D. of normalized (luciferase units/beta
galactosidase) luciferase measurements relative to vehicle control. (H) SREBP1c regulates
endogenous GLDC mRNA levels. GLDC mRNA levels after transient transfection of
pcDNA3.1-SREBP1c in HEK293T cells. Data are mean + S.D., n=3; **P<0.01.
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3.3.5 Hormonal regulation of GLDC in rat primary hepatocytes
The fact that GLDC levels are elevated by fasting suggests that GLDC gene expression
might be regulated by glucagon. Since our H4IIE cells did not show a robust response to cAMP
(Figure 3.1 A), we examined this possibility in rat primary hepatocytes, which are considered
a gold standard for hepatic gene expression studies. To determine if GLDC was regulated by
glucagon or its downstream signal, we treated primary hepatocytes with either vehicle, dbcAMP (100 µM) or glucagon (100 nM) for 12h. GLDC expression was stimulated 18.1 fold by
db-cAMP (P<0.0001) and by 17.5 fold by glucagon (P<0.0001) (Figure 3.6 A). PCK1 and
FASN served as controls and responded as expected to both db-cAMP and glucagon (Figure
3.6 B and C). The changes in GLDC mRNA levels were reflected in the levels of GLDC protein
(Figure 3.6 D). Of the four genes that comprise the glycine cleavage system, only GLDC was
responsive to db-cAMP treatment (Figure 3.6 E).
We also examined the effect of insulin on GLDC expression in primary hepatocytes.
Similar to the H4IIE cells, although to a lesser degree, insulin stimulated GLDC transcription
(1.7 fold, P=0.019) in primary hepatocytes (Figure 3.6 F). To confirm the insulinresponsiveness of the cells, we measured the response of FASN and PCK1 mRNA levels to
insulin treatment. Insulin stimulated FASN mRNA Figure by 2.34 fold (P=0.0002) (Figure 3.6
F) and suppressed the gluconeogenic gene PCK1 by 5.68 fold (P=0.0064) (Figure 3.6 F).
Together these data indicate that glucagon is a potent inducer of GLDC gene transcription, and
suggest that insulin, while also a positive regulator of GLDC expression, may function to
maintain basal levels of GLDC expression.
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Figure 3.6: Regulation of GLDC by glucagon, cAMP and insulin in rat primary
hepatocytes
48h after plating, rat primary hepatocytes were treated with either vehicle, db-cAMP (100 µM)
or glucagon (100 nM). After 12 hours of incubation, cells were harvested for total RNA
extraction and analysis by RT-qPCR. The abundance of (A) GLDC mRNA, (B) FASN mRNA
and (C) PCK1 mRNA in total RNA was analyzed by 2-∆∆Ct method and quantitated by RTqPCR. PPIB was used as a reference gene. Error bars, mean + S.D.; *P<0.05, **P<0.01,
***P<0.001. The results were confirmed with at least 3 independent rat hepatocyte preparations.
(D) 48h after plating, rat primary hepatocytes were treated with either vehicle, db-cAMP (100
µM), glucagon (100 nM) or insulin (100 nM) for 8, 24 and 48h and GLDC protein was analyzed
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by western blot. Actin was used as a loading control. (E) The abundance of AMT, DLD, and
GCSH, the other components of the glycine cleavage system, was measured in hepatocytes
treated with either vehicle or db-cAMP (100 µM). After 12 hours of incubation, the abundance
of AMT, DLD, and GCSH mRNA in total RNA was analyzed by 2-∆∆Ct method and quantitated
by RT-qPCR. PPIB was used as a reference gene. Error bars, mean + S.D.; *P<0.05, **P<0.01,
***P<0.001. The results were confirmed with at least 3 independent rat hepatocyte preparations.
(F) 48h after plating, rat primary hepatocytes were treated with either vehicle or insulin (100
nM) for 12h, and GLDC, FASN, and PCK1 mRNA abundance was analyzed by
2-∆∆Ct method and quantitated by RT- qPCR. PPIB was used as a reference gene. Error bars,
mean + S.D.; *P<0.05, **P<0.01, ***P<0.001. The results were confirmed with 3 independent
rat hepatocyte preparations.
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3.3.6 CREB1 and ATF1 mediate cAMP-dependent activation of GLDC
The glucagon-cAMP signaling pathway leads to the activation of CREB family
(CREB1, ATF1, and CREM) transcription factors, which are known to mediate transcriptional
effects of glucagon on the expression of many fasting-induced genes. In ENCODE database
for CREB ChIP-seq, there were some putative binding sites for CREB transcription factors in
the GLDC promoter. To determine if CREB proteins also mediate the effects of glucagon on
GLDC expression, we performed siRNA mediated CREB1 and ATF1 knockdown in primary
hepatocytes (Figure 3.7). Knockdown of CREB1 (isoform A and B) and of ATF1 reduced the
ability of db-cAMP to stimulate GLDC transcription (Figure 3.7 A). The effect of CREB1
knockdown was seen at GLDC protein levels as well (Figure 3.7 B). CREB1 and ATF1 are
known to either homodimerize or heterodimerize to regulate target gene expression. When we
performed a double knockdown of CREB1 and ATF1, we did not see a stronger reduction of
GLDC mRNA (Figure 3.7 A) than either individual knockdown. This suggests that the
configuration of CREB transcription factors with regard to GLDC expression is a CREB1 and
ATF1 heterodimer.
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Figure 3.7: CREB1 and ATF1 mediate cAMP-dependent activation of GLDC
(A) GLDC mRNA abundance with cAMP stimulation in rat primary hepatocytes transfected
with siRNA against CREB1 and/or ATF1. (B) Transfection of siRNA against scrambled control
and Creb1 in rat primary hepatocytes for 48h and then treated with either vehicle (veh) or cAMP
for 20h. GLDC, p-Creb and total Creb protein levels quantified by western blotting normalized
to Ponceau staining of the membrane. (C) Creb1 isoform A mRNA, (D) Creb1 isoform B
mRNA, and (E) ATF1 mRNA knockdown in rat primary hepatocytes was confirmed by RTqPCR. Error bars, mean + s.d.; *P<0.05, **P<0.01, ****P<0.0001. The results were confirmed
with at least 3 independent rat hepatocyte preparations.
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3.4 Discussion
In the previous chapter, we showed that hepatic GLDC expression was stimulated by
fasting and in two mouse models of diabetes, and proposed that this effect contributed to the
reduced glycine observed in those states. The objective of the work described in this chapter
was to identify the specific signaling pathways and transcriptional mechanisms responsible for
the regulation of GLDC expression in these states. Type 2 diabetes is accompanied by high
levels of circulating insulin, glucagon, and glucocorticoids depending on the stage of the
disease and its etiology. Given that these hormones can all stimulate GLDC expression, it
seems likely that the reduced levels of glycine seen in both early and late-stage diabetes and in
other metabolic disease syndromes such as obesity and NAFLD are due, at least in part, to
elevated expression of GLDC mediated by one or more of these hormones.
We found that GLDC was positively regulated by the metabolic hormones glucagon,
insulin, and cortisol. We further demonstrated that glucagon modulates GLDC expression via
the PKA-mediated activation of CREB1/ATF1 transcription factors. We also presented data
strongly suggesting that SREBP1c mediates the insulin effect on GLDC transcription. Given
that we did not observe any effect of glucose levels on GLDC expression, we conclude that the
primary regulatory pathways acting on GLDC, in this context, are hormonal. Of particular
interest, in H4IIe cells, insulin was the dominant hormone for the regulation of PCK1 gene. In
these cells, PCK1 was unresponsive to glucagon-mediated stimulation and at the same time
hypersensitive to insulin-mediated suppression of gene expression. In rat primary hepatocytes,
which more closely resemble liver cells in vivo than H4IIE hepatoma cells, glucagon was the
dominant hormone. This is consistent with a previous report that shows the flux of the glycine
cleavage system is stimulated with glucagon (121).
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Our observation that glucagon only stimulates GLDC and not the other components of
the glycine cleavage system is consistent with the idea that GLDC is the rate-limiting
component of the glycine cleavage system and the key enzymatic pathway that controls blood
glycine levels (122).
What could be the physiological significance of GLDC regulation by glucagon?
Glycine catabolism by the glycine cleavage system is an essential metabolic process that feeds
into the one-carbon pathway system. The flux through the glycine cleavage system has been
shown to be stimulated by glucagon (121) and high-protein meal (123). We have shown that
fasting, glucagon, and cAMP stimulate GLDC gene expression. Glucagon is known to
stimulate the flux through oxidative phosphorylation (124-126). We speculate that the
physiologic significance of glucagon regulation of GLDC is to meet cellular energy
requirements in the form of ATP through mitochondrial respiration and stimulation of
gluconeogenesis during the fasted state. One of the products of glycine catabolism is the
production of NADH (70) which can be utilized towards glucose production through two
routes. This mitochondrial NADH can donate electrons to the electron transport chain to
generate ATP (127) which would allow ATP-dependent processes such as pyruvate
carboxylation to proceed at a faster rate aiding gluconeogenesis (128). Mitochondrial NADH
can be shuttled to the cytosol by the malate-oxaloacetate shuttle, thereby contributing to the
cytosolic NADH pool required for gluconeogenesis (129). The speculation of the link between
GLDC and gluconeogenesis is further supported by the hepatic and renal distribution of GLDC
(69, 98) which are main sites of glucose production. Even within the metabolic zonation of the
liver, GLDC is expressed in the periportal region which is the site for gluconeogenesis (130).
A curious aspect of our findings is that both glucagon and insulin stimulate GLDC.
These are generally considered counter-regulatory hormones. For example, PCK1 is stimulated
by glucagon and suppressed by insulin. The only other gene that we know of that is similarly

67

regulated by insulin and glucagon is FGF21 (regulator of carbohydrate and lipid metabolism).
FGF21 expression is cooperatively stimulated by both insulin and glucagon (neither hormone
had an effect on its own (131). GLDC regulation differs from FGF21 in that it was stimulated
by the individual hormones, and that they did not appear to function in a cooperative manner.
Are there any physiological circumstances where glucagon and insulin might act
together to enhance GLDC expression?- The only circumstance where the production of both
hormones by the pancreas occurs simultaneously is after a pure protein meal. In these
circumstances it may be beneficial to have an elevated GLDC expression and glycine
degradation.

In fact, it is known that glycine levels are reduced by a high protein diet,

consistent with this idea that GLDC expression is elevated under these circumstances. A highprotein diet in rats is associated with reduced plasma glycine levels as compared to rats fed a
low or normal protein diet (132). There is an increased hepatic uptake of glycine after rats are
fed a high-protein diet (133). Even with the increased uptake, liver tissue glycine levels are
reduced as seen in a study with rats adapted to a 5, 13, and 50% casein diet for 21 days, and
liver glycine levels were 4830, 2080, and 580 nmoles/gm of liver tissue, respectively (134).
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In addition, it has been shown that the flux through the hepatic glycine cleavage system
is rapidly stimulated with a high-protein meal (123). In rats adapted to a high protein vs a low
protein diet for 24 days, the diurnal glycine levels increased during the daytime on the highprotein diet. But the glycine levels were overall 3-4 fold lower at all times on a high-protein as
compared to a low-protein diet (135).
An interesting finding was the requirement of serum in growth media to maintain
GLDC expression levels. In the absence of serum, insulin alone was able to maintain GLDC
expression levels in H4IIE cells. This observation suggests that insulin acts mainly to ensure a
basal level of expression of GLDC expression, for example after a meal when glucagon is
absent but when it would still be beneficial to have a functional glycine cleavage system.
The involvement of glucocorticoids in nutritional regulation of gene expression is
somewhat complicated. Cortisol promotes protein catabolism (136), enhances gluconeogenesis
(111), and in chronic excess (such as in Cushing’s disease) causes insulin resistance (137). Our
data revealed that insulin and dexamethasone had an additive effect in the stimulation of GLDC
mRNA levels although we did not study the glucocorticoid regulation of GLDC in detail.
We tried using an SREBP1c dominant negative expression plasmid as well as siRNA
against SREBP1c to reduce SREBP1c expression in H4IIE cells, treat the cells with insulin and
meaure GLDC and FASN mRNA and protein levels. We were unable to see any effect of
reducing SREBP1c expression on FASN or GLDC expression. Although we were not able to
experimentally prove that the regulation of GLDC by insulin occurred through an SREBP1c
pathway, we did clearly demonstrate that SREBP1c can stimulate GLDC gene expression.
Given the well-characterized role of SREBP1c in insulin-mediated regulation of various
hepatic genes such as FASN (138), it seems likely that stimulation of GLDC expression by
insulin is also mediated by SREBP1c.
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CREB1 and ATF1, well-characterized transcription factors, are targets of the cAMPinducible PKA-mediated phosphorylation required for transcription activation. CREB1 and
ATF1 are known to either homodimerize or heterodimerize to regulate target genes (139). We
found that the configuration of CREB1 and ATF-1 heterodimer might be regulating GLDC
transcription. This would be similar to glucagon-PKA-CREB regulation of other metabolic
genes such as PCK1 and G6PC (140-143). Our observations that GLDC is upregulated by
fasting and is positively regulated by glucagon is consistent with human studies on the
metabolic effects of altering glucagon levels. A study by Boden et al. (1984) performed in 6
healthy normal-weight human subjects demonstrated the effects of selective glucagon
deficiency (intravenous infusion of somatostatin + insulin) and excess (intravenous infusion of
somatostatin + insulin + glucagon) on 21 plasma amino acids. From that panel, one of the
largest changes was observed in glycine levels which increased (+24%) with glucagon
deficiency and decreased (-20%) with glucagon excess (144). One of the frequently observed
characteristics of type 2 diabetes is hyperglucagonemia (145, 146) and it is possible that
reduced levels of glycine seen in diabetes and related disorders are due specifically to
glucagon-mediated stimulation of GLDC gene expression. The role that this elevation of
GLDC gene expression and accompanying reduction in glycine levels play in the development
of diabetes requires further investigation.
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- IMPACT OF ALTERED GLDC GENE EXPRESSION ON CELLULAR
PHYSIOLOGY.

4.1 Introduction
The glycine cleavage system, and in particular the rate-limiting enzyme GLDC, are
major determinants of glycine levels in circulation. This is illustrated most clearly by the effect
of inherited inactivating mutations in GLDC, which cause extreme elevation of blood glycine
levels and a condition referred to as non-ketotic hyperglycemia which is characterized by
neurological and developmental disorders (77, 80, 81, 84). Similar effects are seen in animal
models. As shown in Figure 4.1 B, loss of GLDC expression and its enzymatic activity in mice
(using a gene-trap methodology) showed a significant increase in mean plasma glycine levels:
889 µM compared to 239 µM in wild-type mice (77). The key role of GLDC in determining
glycine levels is clearly seen in cell culture experiments where overexpression of GLDC led to
a reduction in glycine levels in both HLF and NIH 3T3 cells, and retroviral knockdown of
GLDC in A549 cells led to an increase in glycine levels as measured by LC-MS based
metabolic profiling (Figure 4.1 A) (86).
An aberrant overexpression of GLDC is observed in various types of cancers, barring
a single report of GLDC promoter hypermethylation and silencing in gastric cancer (91).
GLDC is overexpressed in the tumor-initiating cells in non-small cell lung cancer (86), breast
neoplasms (88), glioblastoma multiforme (87), and prostate adenocarcinoma (147). Whether
there exists a relationship between changes in GLDC expression observed in different cancer
types and in our results is unclear. But there is a report that shows a decrease in plasma glycine
levels in lung cancer patients (148).
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Figure 4.1: Effect of altering GLDC on glycine levels.
(A) Overexpression of GLDC in 3T3 and HLF cells, knockdown of GLDC in A549 cells and
relative fold change in glycine and glycine related metabolites (86). (B) Elevated glycine
concentrations in plasma and urine of GT1/+ and GT1/GT1 (GLDC gene trap models) mice as
compared to GLDC+/+ mice (77).
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As reviewed in Chapter 1, glycine and its metabolic derivatives are deeply integrated
into a variety of critical metabolic pathways. Of particular interest is its role in the biosynthesis
of glutathione, the principal cellular antioxidant. Glycine is most clearly linked to glutathione
metabolism by the fact that it is one of the three amino acids that compose the glutathione
molecule. It is also possible that the production of 1C groups generated during glycine
catabolism also indirectly contribute to glutathione production. The methylene tetrahydrofolate
generated by GLDC and the glycine cleavage system can be shuttled through the folatemethionine-transsulfuration pathway and end up contributing towards glutathione biosynthesis
by providing carbons for the synthesis of the cysteine needed for the first step in glutathione
synthesis (Figure 4.2). Thus it is possible that altering the levels of GLDC could affect
glutathione production by either reducing the availability of glycine or by increasing the
availability of cysteine. Considering that oxidative stress is one of the hallmarks of type 2
diabetes, alteration in cellular glutathione levels could modify the risk of developing diabetes
or change its rate of progression. Another potential physiological outcome of altered GLDC
expression could be related to another product of glycine degradation by GLDC: NADH. As
the mitochondrial glycine cleavage reaction takes place in the mitochondrial matrix in close
proximity to the electron transport chain, NADH produced from glycine degradation can act as
an electron donor for oxidative phosphorylation and thereby could alter mitochondrial
respiration and energy output.
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Figure 4.2: Role of serine and glycine in one-carbon metabolism.
Adapted from (64)
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4.2 Materials and methods
4.2.1 Plasmid generation and cell line establishment
The construction of the luciferase reporters for GLDC promoter is described in an
article elsewhere (Chen G et al. (2018)).
For stable shRNA-mediated knockdown of GLDC, the pLKO.puro lentiviral smallhairpin RNA vectors against human GLDC (TRCN0000303371) was obtained from Sigma.
The lentiviral packaging strategy has been explained in a previous publication (149). For stable
knockdown of GLDC, HepG2 cells were infected with pLKO.puro-GLDC and selected with 2
µg puromycin/ml. The puromycin-resistant cells were validated for altered GLDC expression
by western blotting.
For stable Crispr/Cas9-mediated GLDC knockout, the construction of the targeting
vector against human GLDC, the sgRNA sequence was determined based on the strategy
explained

in

a

previous

article

(150).

The

designed

sgRNA

sequence

GGGTCTTTTCAAACGGATGT was annealed and cloned into pSpCas9(BB)-2A-Puro
(Addgene) and used for generation of the targeting vector that was transfected into HEK293A
cells using Lipofectamine 2000 (Invitrogen). The puromycin-resistant cell clones were selected
on 1 µg puromycin/ml and screened for loss of GLDC protein expression by western blotting.
For stable GLDC knockdown or knockout cells, individual colonies were isolated from
a heterogeneous pool for experiments. Cells were serially diluted and plated for distinct isolated
colony formation. These colonies were then picked under a light microscope placed inside a
laminar air flow cabinet. Each coloniy was trypsinized and plated in a well of a 48 well tissue
culture plate and incubated until cells reached confluence of 75-80%. Cells were subsequently
moved into a 12 well plate and then into a 6 well plate. Knockdown or knockout of GLDC was
confirmed by western blotting.
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4.2.2 Western blot analysis from cultured cells
Cultured cells were washed twice with ice-cold phosphate-buffered saline (PBS),
scraped off the plates, and lysed in RIPA lysis and extraction buffer (Thermo Scientific) with
protease inhibitors followed by sonication for 30 seconds. Protein concentrations were
determined with the Pierce BCA protein assay kit (Thermo Scientific). Cell lysates (40 µg)
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
and proteins were transferred onto nitrocellulose membranes (Bio-Rad). The membranes were
blocked with 5% non-fat dry milk in PBS, pH 7.4, containing 0.1% Tween-20 (PBST).
The protein bands were visualized with enhanced chemiluminescence reagents (Perkin
Elmer). Primary antibodies used GLDC (Sigma), AMT (Sigma), DLD (Sigma), phosphoCREB (CST), total CREB (CST), GAPDH (Santa Cruz), and Actin (Sigma). The signal was
visualized using Azure c600 imaging system (Azure Biosystems). Ponceau staining of the
membrane was used in some cases for normalizing the protein band intensity.
4.2.3 Total glutathione measurement with an enzymatic recycling method
Total glutathione was measured as described in (151). Briefly, HepG2 and HEK293A
cells were cultured for 48h in GMEM media supplemented with 10% FBS, 0.4M serine and
0.4M glycine, 2 mM glutamine, penicillin, and streptomycin. Cells were washed twice with
ice-cold, Ca2+-/Mg2+- free PBS. Cells were harvested with a cell scraper and placed in 1ml
ice-cold PBS. Cells were pelleted by centrifugation at 1000g for 5 min at 4°C. The pellet was
washed with ice-cold PBS twice. The pellet was resuspended in ice-cold extraction buffer
(0.1% Triton-X and 0.6% sulfosalicylic acid in KPE (0.1M potassium phosphate buffer with 5
mM EDTA disodium salt, pH 7.5)) and cells were homogenized with rapid freeze-thaw in
liquid nitrogen, thrice. The suspension was vortexed for 15 sec after each freeze-thaw.
The cells were centrifuged at 3000g for 4 min at 4°C, and the extract was used for GSH
assay. For the assay, all solutions were prepared in 0.1 M KPE buffer, pH 7.5. The assay was
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performed in a 96-well microtiter plate. 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) and
glutathione reductase (GR) solutions were freshly prepared, mixed together, and added at 120
µl to each well. After allowing 30 sec for GSSG to be converted to GSH, 60 µl of β-NADPH
was added to each well. The absorbance was read at 412 nm every 30 sec for 2 min (5 readings
in total from 0-120 sec) and was repeated twice for each sample. The rate of 2-nitro-5thiobenzoic acid formation (change in absorbance/min) was calculated. Total GSH
concentration in the samples was determined by using linear regression to calculate the values
obtained from the standard curve. Total GSH was normalized to the amount of protein in a
separate set of samples plated, processed, and harvested at the same time.
4.2.4 Total glutathione measurement using a luminescence-based system
Total glutathione was measured using the GSH/GSSG-glo kit (Promega). Briefly, cells
were plated at 10000 cells/well in a 96-well white wall, clear bottom plate. Cells were cultured
for 48h in GMEM media supplemented with 10% FBS, 0.4M serine and 0.4M glycine, 2 mM
glutamine, penicillin, and streptomycin. Cells were washed once with ice-cold, Ca2+-/Mg2+free PBS. Total glutathione lysis reagent (Luciferin-NT, passive lysis buffer, water) 50 µl was
added to the wells containing no cells (no-cell controls), cells, and to the standard curve wells.
The plate was placed in a plate shaker for 5 min at room temperature. Luciferin generation
reagent (100 mM DTT, glutathione-S-transferase, glutathione reaction buffer) 50 µl was added
to the wells and the plate mixed briefly and incubated at room temperature for 30 min. Luciferin
detection reagent 100 µl was added to the wells, mixed, and incubated for 15 min.
Luminescence was measured on a CLARIOStar plate reader.
4.2.5 ROS measurement using CM-H2DCFDA
General cellular ROS was measured using CM-H2DCFDA dye (Invitrogen). Cells were
plated in black wall, clear bottom 96 well plates at 15,000 cells/well in DMEM complete media
and cultured for 24h. The oxidative stress inducer, tert-butyl hydrogen peroxide (tBHP), was
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added on the cells in DMEM complete media at concentrations indicated in the figures for 4h
at 37°C at 5% CO2. Cells were washed twice with Ca2+/Mg2+- free PBS. CM-H2DCFDA was
added on the cells at a concentration of 10 µM for 30 min at 37°C at 5% CO2 in DMEM
Fluorobrite media (Invitrogen). Cells were washed twice with Ca2+/Mg2+- free PBS. The plate
was read in a fluorescence plate reader set at Ex/Em of ~492-495/517-527 nm. The
fluorescence intensity was normalized to the total protein from the same wells as measured by
the Bradford method.
4.2.6 Measurement of basal oxygen consumption rate
Oxygen consumption rate was measured in intact HepG2 scrambled control and
ShGLDC clones #1 and #3 cells on an XFe24 seahorse bioanalyzer. Before plating the cells the
bioanalyzer plate was coated with gelatin (25 µl/well) and incubated at 37°C for 30 min. Excess
gelatin was removed and the plate air-dried in the hood. 30000 cells per well were plated a
night before. The basal oxygen consumption rate measurements were performed according to
the manufacturer's instructions. After the measurement was complete, cells were lysed with
RIPA (25 µl/well) buffer and equal volumes were loaded on an SDS-PAGE gel. The Western
blot was probed for GAPDH and the band intensity was used for normalization of the oxygen
consumption rate values.
4.2.7 Cell proliferation
HepG2 scrambled control and one clone each isolated from the two shGLDC guide
targeting vectors (3371 and 6601) were plated on 6-cm plates and grown for 4 days in complete
growth media. The seeding density was 25,000 cells/well for each cell type. Cells were washed
with PBS and collected in trypsin. The cells, media and the PBS wash were mixed together and
spun down at 1,000 RPM for 3 minutes at RT in a 15 ml Falcon tube. The pelleted cells were
then resuspended in media and trypan blue staining (Invitrogen) was used to distinguish
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between the dead and living cells. The counting was performed using a hemocytometer under
a light microscope.
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4.3 Results
4.3.1 Establishment of mammalian cell lines with reduced or deleted GLDC.
To understand the impact of altering GLDC expression on cellular physiology, several
stable cell lines with either deleted of reduced expression of GLDC were generated. For GLDC
knockdown in HepG2 cells, we used two targeting vectors against GLDC as described in the
methods section of this chapter. The efficacy of GLDC knockdown using the heterogeneous
cell pools from the two targeting vectors showed a more than 95% reduction in GLDC protein
levels as compared to scrambled control. Measurement of protein levels of GLDC, DLD, and
AMT, components of the glycine cleavage system showed that knockdown is specific to GLDC
with both of the shGLDC targeting vectors (figure 4.3 A). Individual cell colonies were isolated
by selection in 2 µg/ml puromycin from the heterogeneous cell pools and validated for GLDC
knockdown by immunoblotting. The targeting vector 3371 had better efficiency of GLDC
knockdown than targeting vector 6601 (figure 4.3 B). The individual clones generated from
this targeting vector were used in our experiments. We also generated a Crispr/Cas9-mediated
GLDC stable knockouts in HEK293A cells as another cell model system to study the effect of
altering GLDC on cellular function. The methodology of Crispr/Cas9 sgRNA design and
generation of the targeting vector is described in the methods section. Puromycin resistant
heterogenous pool and individual cell colonies were screened for loss of GLDC by Western
blot analysis. Most of the clones showed a complete knockout of GLDC expression (figure 4.3
C). The HEK293A cell line was used as a control. The studies described below used these two
mammalian cell models of GLDC deficiency.
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Figure 4.3: Establishment of stable cell lines with reduced GLDC expression
Western blot analysis to determine (A) GLDC protein expression following shRNA-mediated
knockdown of GLDC in HepG2 cells. Two shRNA constructs (3371 and 6601) were used for
targeting GLDC. Individual clones with stable GLDC knockdown from each construct selected
on 2 µg/ml puromycin were analyzed. Actin was used as loading control. (B) GLDC, DLD and
AMT protein expression following shRNA-mediated knockdown of GLDC in HepG2 cells.
Heterogenous pool with stable GLDC knockdown from 3371 and 6601 shGLDC constructs
selected on 2 µg/ml puromycin were analyzed. GAPDH was used as a loading control. (C)
GLDC protein expression following Crispr/Cas9 genome editing. Independent cell clones
selected on 1 µg/ml puromycin were examined. Actin was used as a loading control.
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4.3.2 GLDC is required for maintaining cellular redox balance.
An important metabolic fate of glycine is as a component of the antioxidant glutathione.
Glutathione is a tripeptide composed of cysteine, glutamate, and glycine, and the addition of
glycine to the cysteine-glutamate di-peptide is the final step in the synthesis of glutathione.
Given the key role of GLDC in regulating glycine availability, we initially hypothesized that
elevated GLDC enzyme levels would lead to a reduction in glycine availability and consequent
reduction in the rate of glutathione synthesis. With this same reasoning, reduced GLDC activity
would increase glycine levels and potentially stimulate glutathione synthesis. To test this
hypothesis, we measured total glutathione levels in cells with suppressed GLDC enzyme levels.
Contrary to our expectations, knockdown of GLDC by shRNA in HepG2 cells (Figure 4.4 A),
or by Crispr/Cas9 mutagenesis in HEK293A cells (Figure 4.4 B), actually resulted in a
significant reduction in total glutathione production; 1.9-fold (P=0.004) and 1.8-fold,
(P=0.025) respectively (Figure 4.4 C and D). These unexpected results suggest that in these
experimental conditions cellular glycine levels are already in excess with regard to glutathione
synthase activity. A potential explanation for these surprising findings is that product(s) of
GLDC activity is required for glutathione synthesis. The most likely possibility is that the
methylene tetrahydrofolate produced by GLDC action enters the folate-methioninetranssulfuration pathway, which is required for glutathione synthesis (Figure 4.2).
To determine if the observed reduction of glutathione synthesis affected cellular
oxidative stress, we measured reactive oxygen species (ROS) levels in the HepG2 cells with
shRNA knockdown of GLDC. Intracellular ROS levels were measured using the CMH2DCFDA dye which is a probe for general ROS levels. We also included a pro-oxidant (tertbutyl hydroperoxide) treatment to determine if the GLDC knockdown reduced the cell’s ability
to mount a protective glutathione-mediated response.
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As predicted from the glutathione experiments described above, the endogenous levels of ROS
were higher in the HepG2 GLDC knockdown clone, 1.76 fold (P=0.0003) (Figure 4.4 E, lefthand bars) as compared to the control cells.
The scrambled control HepG2 cells did not show an increase in ROS species when
challenged with 150 µM of tert-butyl hydroperoxide, indicating that they could mount a
compensatory antioxidant (protective) response (Figure 4.4 E). The GLDC knockdown cells
showed an exacerbated response to the additional stress, with an increase in ROS of 79.4 %
(P=0.0002) after tert-butyl hydroperoxide treatment. Similar results were obtained using the
HEK293A GLDC knockout cell line. In these cells, the reduced glutathione levels induced by
the GLDC knockout resulted in ROS elevation only when an external oxidative stress was
applied (Figure 4.4 F). Together these results indicate that the GLDC-mediated changes in
glutathione production resulted in increased ROS levels and susceptibility to oxidative stress.
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Figure 4.4: GLDC is required for maintaining cellular redox balance
(A) Western blot of HepG2 scrambled control (scr cnt) and GLDC stable knockdown (shGLDC)
cell lines (B) HEK-293A control cell line and CRISPR/CAS9 mediated GLDC stable knockout
(GLDC KO) cell line. In (A, B), β actin was used as a loading control. (C, D) Quantitative
determination of total glutathione levels using an enzymatic recycling method in (C) HepG2
scrambled control and GLDC stable knockdown clone and (D) HEK293A control and GLDC
stable knockout clone. Total glutathione levels were normalized to total protein. Error bars,
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mean + s.d.; *P<0.05, **P<0.01. The results were confirmed with 3 independent experiments.
(E,F) Quantitative measurement of general intracellular oxidative stress in (E) HepG2
scrambled control and shGLDC stable cell line, and (F) HEK293A control and GLDC stable
knockout cell line using CM-H2DCFDA normalized to total protein using a fluorescencemeasurement based plate reader. The cells were either treated with vehicle or tBHP at the
indicated concentrations for 4h prior to dye addition. The results were confirmed with 2
independent experiments. Error bars, mean + s.d.; *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001.
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4.3.3 GLDC mediates cAMP-dependent stimulation of glutathione production.
The experiments described above showing that GLDC knockdown reduces glutathione
production, predict that elevated GLDC levels or activity would increase glutathione levels.
We tested this possibility in primary rat hepatocytes in which GLDC levels were induced by
treatment with db-cAMP. siRNA-mediated GLDC knockdown efficiency achieved in these
cells was 68% (P=0.0164) (Figure 4.5 A). We verified GLDC knockdown as well as db-cAMP
induction at the protein level (Figure 4.5 B). In these primary hepatocytes, db-cAMP treatment
induced GLDC mRNA levels (4.44 fold, P=0.0005) (Figure 4.5 A) and resulted in a significant
increase in total glutathione levels (Figure 4.5 C). This cAMP-mediated increase in glutathione
production was dependent on GLDC since shRNA knockdown of GLDC (Figure 4.5 A and B)
abolished the induction of glutathione production (Figure 4.5 C). These findings confirm that
GLDC activity is linked to glutathione production.
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Figure 4.5: GLDC mediates cAMP-dependent stimulation of glutathione production
(A, B) Verification of knockdown efficiency of siControl and siGLDC in rat primary
hepatocytes either treated with vehicle (veh) or cAMP by (A) RT-qPCR for transcript
abundance and by (B) Western blotting for protein levels normalized to Ponceau staining of the
membrane. (C) Rat primary hepatocytes transfected with either siControl or siGLDC and treated
with cAMP for 18h and total glutathione production measured by luciferase-based GSH assay.
Error bars, mean + s.d.; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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4.3.4 Additional effects of GLDC knockdown: cell proliferation and mitochondrial
respiration.
As mentioned above, GLDC activity could increase energy output in cells via
production of NADH. Thus, reduced GLDC could potentially affect energy requiring cellular
processes, such as proliferation. In fact, cells with loss of GLDC have been reported to display
reduced cellular proliferation rates (86, 147, 152, 153). To study the regulatory effect of GLDC
on HepG2 cell proliferation, 25000 cells from one clone each isolated from the two shGLDC
vectors (3371 and 6601) were plated into 6-cm plates and grown in complete media. The
number of cells present after 4 days was then counted using a hemocytometer. Consistent with
reports in other cell lines, knockdown of GLDC in HepG2 cells reduced cellular proliferation
rates (Figure 4.6 A).
Since NADH produced by GLDC can donate electrons to the mitochondrial electron
transport chain and promote mitochondrial respiration, it is possible that knocking down GLDC
would impair mitochondrial respiration. We therefore measured the basal oxygen consumption
rate (OCR) of HepG2 scrambled control cells and GLDC 3371 targeting vector derived clones
#1 and #3 HepG2 cells on a Seahorse analyzer. The relative OCR of GLDC knockdown clone
#1 was decreased by 20% (P=0.0194) and in clone #3 decreased by 20% (P=0.0067) relative
to scrambled control (Figure 4.6 B). These findings are consistent with the possibility GLDC
activity is required for full mitochondrial respiratory function.

Relative OCR
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Figure 4.6: Loss of GLDC decreases cell proliferation and relative oxygen consumption
rate in HepG2 cells.
(A) Cell proliferation rate of scrambled control and two individual clones isolated using
shGLDC 3371 targeting construct. Cells were grown in DMEM/high glucose media. (B)
Relative basal oxygen consumption rate of scrambled control and two individual clones isolated
using shGLDC 3371 targeting construct. Cells were grown in DMEM/high glucose media. Data
are presented mean + s.d. *P<0.05, **P<0.01. (Student's t-test compared to scrambled control).
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4.4 Discussion
In this chapter, we utilized cell models to study the physiological effects of altered
GLDC expression. As presented in the introduction to this chapter (Section 4.1), a primary
effect of reduced or increased GLDC expression in vitro and in vivo is an increase or decrease
in glycine levels, respectively. The goal of the work described in this chapter was to determine
if there were other physiological outcomes of altered GLDC expression in addition to changes
in glycine levels. In particular, we proposed that given the requirement for glycine in
glutathione biosynthesis, a stimulation of GLDC would reduce the available glycine pool and
limit the ability of the cell to synthesize glutathione. Our finding that GLDC knockdown
produced the opposite effect disproved this original mechanistic hypothesis and suggested that
there was some other less well-understood link between GLDC and glutathione production.
Using established stable cell lines with reduced GLDC expression we were surprised
to observe that reduced GLDC expression caused a suppression of total glutathione levels and
an increase in ROS levels. One of the reasons our initial hypothesis was incorrect might be
related to the in vitro cell culture circumstances. These in vitro experiments were performed in
growth media containing 300 µM glycine, well in excess with regard to the enzyme glutathione
synthase, which adds glycine to the cysteine-glutamate dipeptide to form glutathione. It would
be interesting to perform total glutathione measurements with varying glycine concentrations
in the growth media.
Our findings led us to propose that the product of glycine cleavage by GLDC, 5,10meTHF, is an input into the one-carbon metabolism cycle. One of the outputs of this system is
glutathione production through the transsulfuration pathway (based on figure 1.3 and 1.4),
which could be the mechanistic link between GLDC and glutathione production.
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These results raise the question- Why does a reduction in GLDC expression lead to
reduced glutathione production? The glycine cleavage system is linked with the one-carbon
metabolism which is comprised of the folate cycle (mitochondrial), methionine cycle
(cytosolic), and the transsulfuration pathway (cytosolic). One carbon metabolism directly
controls serine, glycine, and methionine levels and indirectly controls cysteine levels.
Homocysteine transfers sulfur to serine to make cysteine via the transsulfuration pathway. The
notable aspect of our findings is that reducing the levels of a mitochondrial enzyme (GLDC),
caused a significant reduction in a product being generated in the cytosol (glutathione), even
in the presence of excess glycine. Amplification of GLDC expression in certain cancers suggest
that the mitochondrial glycine cleavage system is important as a source of one carbon units.
Loss of function mutations in glycine cleavage system components cause an elevation in
embryonic tissue glycine levels (77). We already know in vitro GLDC knockdown leads to an
increase in glycine. This implies that the decline in glutathione levels observed upon GLDC
knockdown are not due to a deficiency of glycine for the last step of glutathione biosynthesis.
Labuschagne et al. (2015) showed glutathione levels were relatively unaffected across varying
concentrations of serine and glycine in DMEM media containing 17 mM glucose. These cells
had functional glycine cleavage system as well as other serine/glycine biosynthetic enzymes
which implies the cells can generate serine and glycine from glucose in the media, if needed
(154). These results were also supported by Ducker et al. (2016) who showed in HEK293T
cells with functional serine/glycine pathway enzymes, glutathione levels are unaffected in
glycine depleted media. When they disrupted the flow of mitochondrial one-carbon groups by
knocking out either SHMT2 or MTHFD2, there was a decline in glutathione levels upon
glycine depletion but not in glycine replete conditions (155). Leung et al. (2017) showed a
decline in the relative abundance of me-THF in embryos carrying GLDC and MTHFR loss-offunction alleles (156). Although there is no direct evidence that this occurs, but with these
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supporting evidences, we can predict that the decline in glutathione levels after GLDC
knockdown is due to a reduction in the one-carbon groups generated by glycine degradation.
The one carbon groups link to the transsulfuration pathway via cysteine biosynthesis and
therefore contribute to glutathione levels. Formate, the terminal product of the mitochondrial
folate metabolism, is shuttled to the cytosol to meet the one-carbon demands of the cytosolic
folate and methionine pathways (83). It would be interesting to see if formate is able to rescue
some of the effects of GLDC knockdown on total cellular glutathione levels.
Our results in rat primary hepatocytes showing that a cAMP-mediated increase in
GLDC was associated with increased glutathione production is in contrast to a previous study
by Lu et al., (1991), which showed a decline in cellular GSH levels with db-cAMP treatment
in rat hepatocytes (157). The differences in growth medium composition and GSH
measurement method between their study and ours might account for this discrepancy. Our
findings linking GLDC to glutathione production were consistent across multiple cell lines and
knockdown methods.

Also in contrast to our findings, a previous study has shown that

knocking down GLDC in Huh7 cells resulted in an increase in total glutathione levels and a
decreased GSH/GSSG ratio in their experimental system (158), essentially the opposite of our
results. We saw a decrease in total glutathione levels after knocking down GLDC in HepG2
and HEK293A cells but were unable to effectively measure GSH/GSSG ratio. However,
similar to Zhuang, Li et al. (2018), we saw an increase in reactive oxygen species. It may be
worth noting that the effect of GLDC knockdown on cell migration, invasiveness, and
metastasis by (158) was in contrast to most reported effects of GLDC on cancer progression
(159).
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In summary, the work presented in this chapter identified a previously unidentified link
between a mitochondrial enzyme, GLDC, and the antioxidant glutathione possibly connected
via mitochondrial folate-mediated one-carbon units from glycine cleavage supporting cytosolic
glutathione production and thereby redox balance.

93

- FINAL CONCLUSIONS AND FUTURE DIRECTIONS

The overall goals of my thesis work were to provide a mechanistic explanation for the
longstanding observation that glycine levels are suppressed in obesity, diabetes, and related
metabolic diseases, and to explore the possibility that altered glycine metabolism played a role
in the development of these syndromes. The work was organized around the hypothesis that
GLDC, the rate-limiting enzyme in glycine degradation, is a central regulator of glycine
metabolism responsible for determining glycine levels and linking glycine metabolism to
physiological pathways related to metabolic disease. For this reason, we (1) examined the
expression of GLDC under metabolic and nutritional stress conditions, (2) identified the
hormonal regulation and signaling pathways involved in the transcriptional regulation of
GLDC, (3) determined the impact of altering GLDC expression on cellular physiology.
Our data demonstrated that GLDC expression is altered in mouse models of type 2
diabetes and by fasting and that hormones associated with metabolic and nutritional regulation
(glucagon and insulin) are key regulators of GLDC gene expression. We speculated that there
exists a link between GLDC and gluconeogenesis via one of the products of glycine cleavageNADH (See Chapter 3 ‘discussion’). To confirm this idea, future work should include
measurement of ATP levels, mitochondrial membrane potential, and NAD+/NADH ratio in
cells with altered GLDC levels after db-cAMP treatment. It will be interesting to measure
glucose production in cells with GLDC knockdown after db-cAMP treatment. Cells can be
provided with either lactate or pyruvate as substrates the night before and then treated with dbcAMP for 8h to stimulate gluconeogenesis. We expect a decline in glucose production in cells
with reduced GLDC levels.
Finally, we demonstrated that GLDC activity is linked to glutathione production. We
think that altering GLDC causes metabolic rearrangements and an alteration in the one-carbon
flux through the mitochondrial folate pathway (see figure 1.4), the interlinked cytosolic
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methionine cycle, and consequently in the activity of the cytosolic transsulfuration pathway
which generates the cysteine required for glutathione biosynthesis (see figure 1.3). To confirm
this idea, future work using metabolic flux analysis needs to be conducted by replacing glycine
in growth media by labeled glycine (U-13C glycine) and then monitoring the kinetics of labeled
glycine incorporation into cells and the downstream metabolic product, glutathione. It will be
interesting to measure if formate is able to rescue the effects of GLDC suppression in vitro by
providing one-carbon units that can be freely exchanged between the mitochondrial and
cytosolic folate pathway. Given the crucial role of glutathione in normal physiology and in
metabolic pathologies, this functional link between GLDC and glutathione that we identified
suggests a pathway by which alterations in glycine catabolism could play a functional role in
the development of diabetes and related metabolic diseases. Our data also demonstrated that
knocking down GLDC influenced various cellular physiology parameters. Knocking down
GLDC led to a decrease in cell proliferation and mitochondrial oxygen consumption rate. In
cells expressing stable reduction in GLDC expression, total glutathione levels were
significantly reduced with an expected concomitant increase in cellular ROS levels.
Going forward, a careful assessment of the altered GLDC expression in vivo will be
required to understand if there exists a causal link between GLDC expression, glycine levels,
redox balance, and susceptibility for metabolic disease development and/or progression.
Briefly, for this assessment, two models will be used: (1) WT-GLDC overexpression, and (2)
shRNA-mediated GLDC knockdown. Recombinant adeno-associated viruses with liver
tropism will be used for hepatic GLDC overexpression or knockdown. 4 weeks after viral
injection, the mice will be placed on either a diabetogenic high-fat diet (65% calories from fat)
or a low-fat diet (10% calories from fat) for 16 weeks. Body composition (Echo-MRI), glucose
tolerance, insulin tolerance, and whole-body energetics (metabolic cages) will be measured at
regular intervals. Glycine levels will be measured by mass spectrometry. Total glutathione and
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GSH/GSSG ratio will be measured both in blood and tissue using commercial kits. We expect
to observe a reduction in glycine, an increase in total glutathione with GLDC overexpression
and vice versa. It would be interesting to see if and how altering hepatic GLDC and then
inducing diabetes would affect the progression of the metabolic disease in a whole-animal
physiology.
Our results add to our understanding of how glycine metabolism is integrated into the
complex metabolic networks responsible for general physiological homeostasis and lay the
groundwork for future studies exploring the mechanistic detail of the metabolic relationships
we have identified. The long-term hope is that the information generated here and in followup studies will suggest pathways for the development of novel therapeutics to treat or prevent
type 2 diabetes and related diseases.
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ABSTRACT
HORMONAL REGULATION OF GLYCINE DECARBOXYLASE AND ITS
METABOLIC OUTCOMES
by

RUTA MILIND JOG
DECEMBER 2020
Advisor: Dr. Todd Leff and Dr. Jian Wang
Major: Pathology
Degree: Doctor of Philosophy
The amino acid glycine is involved in generation of multiple critical metabolites
including glutathione, heme, and creatinine. Interestingly, in both humans and rodents,
circulating glycine levels are significantly reduced in obesity, glucose intolerance, type II
diabetes and non-alcoholic fatty liver disease. The glycine cleavage system is the predominant
glycine degradation pathway in humans. The rate-limiting enzyme of glycine cleavage system
is glycine decarboxylase (GLDC), and loss-of-function mutations of GLDC cause
hyperglycinemia. Here, we show that GLDC gene expression is upregulated in livers of mouse
models of diabetes and diet-induced obesity as well as in the fasted state in normal animals. In
exploring the hormonal signals that mediate these regulatory events we found that both
glucagon and insulin stimulated GLDC gene expression. In primary rat hepatocytes, GLDC
expression was strongly stimulated by glucagon and cAMP, and mildly with insulin while in a
rat hepatoma cell line, insulin strongly stimulated GLDC expression as compared to cAMP.
We identified both cAMP-response element binding protein 1 (CREB1) and activating
transcription factor 1 (ATF1) as mediators of the glucagon regulation, while insulin responsive
transcription factor sterol regulatory element binding protein 1c (SREBP1c) mediated the
insulin stimulatory effect on GLDC transcription. We also observed that altering GLDC
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expression levels strongly affected intracellular glutathione levels and levels of reactive oxygen
species (ROS). Our findings suggest that the hormonal regulation of GLDC may contribute to
a compensatory increase in glutathione production as a defense against metabolic diseaseassociated oxidative stress.
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